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Serotonin (5-HT) receptors represent a class of receptors involved in a variety of 
physiological processes including regulation of mood, perception, cognition, appetite, and heart 
function, and thus serve as drug targets of several drugs such as antipsychotic agents, 
hallucinogenic drugs, and appetite suppressant drugs. Due to the structural similarity of certain 
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5-HT receptor subtypes, particularly 5-HT2 receptors (5-HT2A, 5-HT2B receptors) determination 
and refinement of pharmacophore models of these receptor subtypes can greatly improve the 
therapeutic efficacy of drugs that target them. 
The goals of this study were to define and/or refine existing pharmacophore models for 5-
HT2A and 5-HT2B receptors. Investigation of 5-HT2A receptors involved analysis of a previously 
published pharmacophore for 5-HT2A receptors based on the structure of the atypical 
antipsychotic risperidone. Investigation of a 5-HT2A receptor agonist quipazine and its positional 
isomers/analogues also aided in the elaboration of 5-HT2A receptor binding. Finally, to determine 
structural requirements for 5-HT2B agonist action, a series of phenyl-substituted amphetamine 
analogues and a series of 4-substituted-2,5-dimethoxyamphetamines (DOX-type 
phenylisopropylamine compounds) were analyzed for their 5-HT2B receptor functional activity. 
In the present study, a previously known pharmacophoric 5-HT2A antagonist compound 
was synthesized along with its N-propyl analogue. The pharmacophoric compound, along with 
several others in a series in which the piperidine substituent varies in both length and bulk, were 
screened across serotonin, dopamine, and adrenergic receptors to determine if high affinity and 
selectivity can be achieved for 5-HT2A receptors. The affinity screen revealed that, as the size and 
bulk of the piperidine substituent increases, affinity and selectivity for 5-HT2A receptors increased 
albeit with an accompanying increase in D2 receptor affinity – antagonism at D2 receptors is 
responsible for extrapyramidal stimulation (EPS) symptoms associated with several 
antipsychotics. Because D2 receptor affinity could not be abolished, it was determined that 
extending the chain size of the piperidine substituent is not an effective method for achieving more 
selective 5-HT2A antagonists. 
Computational analysis of quipazine and its analogues was conducted to determine their 
binding modes at 5-HT2A receptor crystal structures. Higher affinity ligands 1-NP and 2-NP were 
found to bind in a distinct pocket relative to the lower affinity ligands quipazine and isoquipazine. 
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It was predicted that the binding pocket occupied by 1-NP and 2-NP contains numerous 
hydrophobic amino acids and that hydrophobic interactions with these residues confer the high 
affinity for this class of compounds. 
Finally, evaluation of 5-HT2B receptors involved analyzing several 5-HT2B ligands in a Ca2+-
release assay to determine their functional activity. In particular, analogues of norfenfluramine 
(nFen) and DOB were analyzed and it was determined that the agonist activity of nFen is driven 
by hydrophobic interactions of its 3-CF3 substituent. To determine the SAR of related 
phenylisopropylamines at 5-HT2B receptors, a series of DOX analogues was analyzed for their 
functional activity. It was discovered that larger, more lipophilic 4-position halogens such as 
bromine (DOB) and iodine (DOI) are more accommodated than smaller less lipophilic halogens 
such as fluorine (DOF). Supporting the importance of a hydrophobic interaction with the 4-position 
substituent, DOPR and DOTB containing propyl and t-butyl 4-position substituents, respectively, 
produced potencies on par with that of DOI. These studies resulted in formulation of the first ever 








Serotonin (5-HT) is a monoamine neurotransmitter that binds to and elicits many of its 
effects through serotonin receptors (5-HT1-7 family of serotonin receptors). Serotonin, along with 
all other monoamine neurotransmitters, contains a common scaffold: a basic nitrogen atom 
separated by a two-carbon alkyl chain from an aromatic moiety. The similarity of the structures of 
monoamine neurotransmitters (e.g., serotonin, dopamine, norepinephrine, epinephrine) is 
representative of the similarities in the binding site residues of all monoamine receptors. Thus, 
many drugs designed to target one of these receptors are likely to also display activity at the 
others, making the designing of selective compounds a challenging task. However, techniques 
such as the application of the Deconstruction, Reconstruction, and Elaboration (DRE) approach 
and the development of pharmacophore models can greatly ease difficulties in this area by 
determining minimal structural features necessary to produce biological activity. Once a simple 
scaffold is established, it can be elaborated by the addition of substituents that might result in 
selective compounds. This project is concerned with the development/refinement of 
pharmacophore models for 5-HT2A and 5-HT2B receptors. 
One area in which the development of more selective compounds can have an enormous 
impact is antipsychotic therapy. The issue with current antipsychotic drugs is that although they 
antagonize the desired 5-HT2A receptor, they also display desired antagonism at D2 receptors. 
This D2 antagonism also underlies the undesired extrapyramidal stimulation (EPS) side effects 
observed in patients prescribed certain antipsychotic medication. Unfortunately, although current 
antipsychotic drugs are very effective in treating schizophrenia, EPS symptoms cause patients to 
experience Parkinsonism-like symptoms such as tremors and dyskinesia. Thus, the development 
of more selective 5-HT2A antagonizing antipsychotic agents would alleviate the suffering 
experienced by millions of schizophrenic patients around the world. Here, we attempt to exploit a 
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new 5-HT2A receptor antagonist pharmacophore to identify compounds with an improved 5-HT2A 
receptor versus D2 receptor profile. 
Quipazine, a known but relatively non-selective 5-HT2A receptor agonist, represents an 
enigmatic ligand in that it does not conform to the structures of other known 5-HT2A agonists. In 
as much as it might provide new insight to how quipazine interacts with the receptor, quipazine, 
a related agonist, 2-NP, and two structurally-related antagonists will be examined at models of 
the active and inactive states, respectively, of 5-HT2A receptor models. 
Unlike 5-HT2A receptors which are mostly expressed in the central nervous system (CNS), 
5-HT2B receptors are mostly expressed peripherally in regions such as the liver, lung, heart, and 
kidney. One region of particular interest is the heart where 5-HT2B receptors regulate proper heart 
morphology and function. In fact, certain drugs such as the very effective anorectic drug 
fenfluramine have been removed from the market due to incidences of cardiac valvulopathy in 
patients – a condition characterized by thickening of the heart valves – resulting from the 
activation of cardiac 5-HT2B receptors. Thus, in the interest of preserving the therapeutic effects 
of these drugs (e.g., anorectic effect of fenfluramine) while dispelling negative side-effects (e.g., 
cardiac valvulopathy) produced by the activation of 5-HT2B receptors, pharmacophoric features 
for activation can be elucidated and these features can be omitted in the structures of drugs 
developed in the future, thus reducing the chances of activating 5-HT2B receptors and producing 
negative cardiac side-effects. These studies will involve molecular modeling, and the synthesis 








A. Overview of Serotonin Receptors 
Serotonin (1) (5-HT, Figure 1), one of the most abundant signaling molecules,1 plays 
numerous physiological roles including the modulation of aggression, appetite, cognition, emesis, 
endocrine function, gastrointestinal function, motor function, neurotrophism, perception, sensory 
function, sex, sleep, and vascular function.1,2 It was initially found in the gastrointestinal mucosa 
(where it is in most abundance and produced by enterochromaffin cells) during the discovery that 
it produced contraction of the smooth muscle of rat uterus in 1937,3 it was later found in the brains 
of numerous animals in 19534 where it is produced by a cluster of cells within the raphe nuclei.5 
Since this discovery, numerous insights have been made in regard to serotonin’s function, 





Figure 1. Structure of serotonin (1). 
 In the human body, serotonin is peripherally biosynthesized primarily in enterochromaffin 
cells and centrally in presynaptic serotonergic neurons, particularly in cell bodies known as the 
raphe nuclei.6 Its synthesis is consistent irrespective of location and involves two steps. First, the 
amino acid tryptophan is hydroxylated at the 5-position of the indole ring by tryptophan 
hydroxylase (TH) using the cofactor tetrahydrobiopterin (THB), forming 5-hydroxy-L-tryptophan 
(5-HTP, Figure 2). Second, 5-HTP is decarboxylated by L-aromatic amino acid decarboxylase 
(AADC) forming serotonin which is then stored in intracellular vesicles in enterochromaffin cells, 
Serotonin (5-HT; 1) 
4 
 
platelets, and serotonergic neurons, ready to be released extracellularly upon external stimuli. 
The binding of serotonin to presynaptic autoreceptors (i.e., 5-HT1A and 5-HT1B receptors) creates 
a negative feedback loop, resulting in the termination of serotonin’s effect via uptake through 
serotonin transporters (SERT) and storage into vesicles or cytoplasmic degradation by 
monoamine oxidase (MAO).6 MAO converts serotonin into 5-hydroxyindoleacetaldehyde which is 
then oxidized by aldehyde dehydrogenase (AD) using the cofactor nicotinamide adenine 
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Serotonin produces its effects through the modulation of proteins known as the serotonin 
receptor family. This family currently consists of seven transmembrane protein subfamilies (5-
HT1-7), of which the 5-HT3 channel is the only ligand-gated ion channel receptor (LGICR) while 
the others are type A rhodopsin-like G-protein-coupled receptors (GPCRs). Serotonin receptors 
were originally classified into two groups, “D” type and “M” type receptors. “D” type receptors were 
found to be involved in the contraction of smooth muscle, the effect of which was blocked by the 
antagonist dibenzyline,8 whereas “M” type receptors, produced a depolarization effect of 
cholinergic neurons that was blocked by morphine.8 In 1979 Peroutka and Snyder reclassified 
serotonin receptors as 5-HT1 and 5-HT2 (previously “D” type receptors) receptors, based on the 
binding of agonists/antagonists at two distinct serotonin binding sites.9 in 1986, Bradley and 
colleagues reclassified type “M” type receptors as 5-HT3 receptors.10 Today, the seven sub-types 
of serotonin receptors are typically grouped according to which G-protein the receptor is coupled 
to during downstream signaling. 5-HT4, 5-HT6, and 5-HT7 receptors are coupled to the G-protein 
Gs which results in the activation of the effector protein adenylyl cyclase (AC) and an increase 
in the levels of the second messenger cyclic AMP (cAMP) , 5-HT1 and 5-HT5 receptors couple to 
Gi/o and deactivate AC and decrease levels of cAMP and 5-HT2 receptors couple to Gq resulting 
in activation of the effector protein phospholipase C (PLC) and increase in the levels of the second 
messenger inositol 1,4,5-triphosphate (IP3) (Figure 3) and diacylglycerol (DAG). Upon IP3 binding 
to IP3 receptors located on the endoplasmic reticulum (ER), Ca2+ is transported from the interior 
of the ER to the cytoplasm (this mechanism serves as a basis for Ca2+ binding assays employed 
to measure functional activity of ligands).11  
The 5-HT2 receptor subfamily consists of three receptor subtypes: 5-HT2A, 5-HT2B, and 5-
HT2C receptors. The 5-HT2A receptor contains a binding site which was originally labeled the “D” 
receptor site. After Leysen et al. discovered a serotonergic component to neurons labeled with 
[3H]spiperone in 1978,12 these receptors were later classified as 5-HT2 receptors by Peroutka and 
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Snyder in 1979. Eventually these receptors were designated 5-HT2A receptors. Examination of 
the distribution of 5-HT2A receptor mRNA in post-mortem humans revealed the presence of mRNA 
in pyramidal neurons (especially in layer V of the neocortex) and in very small levels in the 
hippocampus.13 Positron emission tomography (PET) imaging studies of living human brains 
using the imaging agent N1-([11C]-methyl)-2-Br-LSD ([11C]-MBL) revealed that 5-HT2A receptors 
label highest in regions of the brain associated with cognition and sensory input (e.g., frontal, 
temporal, and parietal lobes) and lowest in regions associated with motor functions such as the 
caudate nucleus and putamen,14 providing evidence for its involvement in the modulation of 
behavior. In the periphery, 5-HT2A receptors have been demonstrated to be expressed in cardiac 
cells and the modulation of cardiac hypertrophy;15 they have also been found on the membranes 







Figure 3. Schematic diagram of classification of serotonin receptors based on their functional 
selectivity.17 
The 5-HT2B receptor, although not called as such at the time, was one of the first serotonin 
receptors to be characterized pharmacologically when in 1957, it was found to facilitate 
contraction of the rat stomach fundus in response to serotonin.18 Unlike 5-HT2A receptors, 5-HT2B 
receptors, originally designated 5-HT2F receptors,19 express very minimally in the central nervous 
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system (CNS) and more so in the human liver, lung, heart, and kidney (as elucidated by northern 
blot containing human RNA samples).20 Immunohistochemical analysis of rat brain sections 
showed that relative to the other 5-HT2 receptors, the few 5-HT2B receptors expressed in the CNS 
display a distribution pattern indicating involvement in locomotion, food behavior, perception, and 
aversion.21 In the lungs, activation of 5-HT2B receptors with dexfenfluramine is shown to lead to 
pulmonary hypertension symptoms independent of a vasoconstriction method,22 indicating its up-
stream involvement in the regulation of proper lung arterial pressure. The most infamous 
involvement of 5-HT2B receptors is in the heart, where they are involved in controlling proper 
morphology and function, an effect which will be discussed in greater detail below.  
5-HT2C receptors, initially labelled 5-HT1C, are shown in rat brains to be expressed in 
highest abundance in the amygdala, choroid plexus, cortex, hippocampus, thalamus, 
subthalamus and in several neurons associated with motor functions.23,24 This receptor is 
implicated in the regulation of anxiety25 and inhibition of drug abuse potential,26 both involving 
their activation. The latter effect is considered to be a result of the inhibition of dopamine release 
upon activation of 5-HT2C receptors.27 These receptors have also been implicated in regulating 
depression as shown by the initial anxiogenic effects of selective serotonin reuptake inhibitors 
(SSRIs) caused by 5-HT2C activation during the first few weeks of administration, followed by the 
intended antidepressant effects coupled with a downregulation of 5-HT2C receptors.28 Lastly 5-
HT2C receptors are thought to be involved in the regulation of obesity. Antagonism of 5-HT2C 
receptors increases food intake and weight gain,29 while 5-HT2C receptor agonists decrease food 






B. Schizophrenia Hypotheses 
1. Serotonin hypothesis of schizophrenia: The serotonin hypothesis of schizophrenia has its 
origins in the pharmacological research of hallucinogens, in particular LSD (2) (Figure 4). Due to 
the structural similarity between LSD and serotonin, in that they both contain an indolamine 
structural scaffold, and the similarity between the hallucinogenic effects of LSD and the psychotic 
symptoms of schizophrenia, research commenced into the possible relationship between 
serotonin and schizophrenia.31 Studies showing that indoles antagonize the effects of serotonin, 
in particular LSD antagonizing the contraction of uterine smooth muscle in rats,32 led researchers 
to initially believe that schizophrenia resulted from a reduction of serotonergic activity in the brain. 
This version of the serotonin hypothesis was amended, when numerous pharmacological studies 
were conducted revealing the similarities between the action of serotonin and LSD,33,34 
Specifically it was revealed that LSD produced contraction of oligodendroglia similar to that 
produced by serotonin, an effect that was not blocked by serotonin.34 Moreover, LSD stimulates 
the hearts of clams and raises the blood pressure of anesthetized dogs, similar to serotonin.33 
The dissimilarities in the mouse behavioral effects between administration of LSD versus other 
antiserotonin agents were also noted.34 The new hypothesis stated that the psychotic symptoms 
of schizophrenia were caused by an excess, as opposed to a deficit, of serotonergic activity in 
the brain. Soon after, researchers turned their interest to other hallucinogens, in particular 
mescaline which has a phenethylamine structural scaffold. It was revealed that mescaline 
produces a cross tolerance with LSD when administered to humans,35 indicating that the two 
compounds with distinct structural scaffolds, could be behaving in a similar manner 
physiologically. Several years later in 1984, Glennon et al. revealed significant correlations 
between the 5-HT2A binding affinities of a series of hallucinogens that included tryptamines and 
phenethylamines and their ED50 values in drug discrimination assays, as well as with their 
hallucinogenic potencies in humans.36 It was later revealed that the schizophrenia-like effects 
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produced by psilocybin, an indoleamine hallucinogen, are blocked by the 5-HT2A antagonist 
ketanserin and the atypical antipsychotic drug risperidone in humans,37 further indicating a 5-HT2A 
involvement in the hallucination symptoms of schizophrenia. 
A more accurate model of serotonin’s involvement in the pathogenesis and pathology of 
schizophrenia is excessive serotonergic activity in certain areas of the brain and diminished 
activity in others, as revealed by examination of postmortem human schizophrenic brains. In these 
studies, serotonin concentration was significantly lower in the hypothalamus, medulla oblongata, 
and hippocampus of schizophrenic brains compared with controls.38 Another group reported 
increased levels of serotonin and its primary metabolite 5-hydroxyindoleacetic acid (5-HIAA) in 
the nucleus accumbens and globus pallidus in postmortem schizophrenic brains.39 Therefore, it 
has been postulated that schizophrenia might be characterized as an “increase in 5-HT 
transmission in subcortical areas…and a decrease in cortical regions.”39 In support of this theory, 
several studies have reported a dysregulation in the density of 5-HT transporters and 5-HT2A 
receptors in the prefrontal cortex of schizophrenic patients.39 
 
Figure 4. Structure of LSD (2). 
2. Dopamine hypothesis of schizophrenia: Interest into the relationship between dopamine and 
schizophrenia began when it was revealed that administration of typical antipsychotic drugs 
haloperidol and chlorpromazine resulted in accumulation of dopamine in mouse brain through 
inhibition of monoamine oxidase (MAO).40 These results in combination with results of a previous 




psychosis,41 can be reversed by administration of the dopamine precursor 3,4-
dihydroxyphenylalanine,42 provided the framework for the dopamine hypothesis of schizophrenia. 
Specifically, it was stated that excessive neurotransmission of dopamine might be one of the 
reasons for psychosis.43 Further studies into the mechanistic relationship between dopamine and 
schizophrenia revealed a reduction of dopaminergic activity in the prefrontal cortex (where D1 
receptors are located) in schizophrenia patients44 and an inverse relationship between prefrontal 
cortex and subcortex (where D2 receptors are located) dopamine levels,44–46 providing evidence 
for a link between schizophrenia and prefrontal hypodopaminergia and subcortical 
hyperdopaminergia. The original hypothesis was further revised to include a theory that negative 
symptoms of schizophrenia are correlated with the former and positive symptoms are correlated 
with the latter.44 The pathophysiology of schizophrenia does not stop with the neurotransmission 
of dopamine as there is also evidence for dopamine neurons innervating and affecting the 
modulation of glutamatergic and GABAergic neurons.47 
 
3. Glutamate hypothesis of schizophrenia: Studies utilizing the general anesthetic phencyclidine 
(PCP) that revealed similarities in the behavioral effects of PCP and the psychotic symptoms of 
schizophrenia48 initiated the research into the possible link between glutamate neurotransmission 
and schizophrenia. PCP was thought to mimic psychotic symptoms more closely than LSD – the 
former producing more of the perceptual and cognitive deficits associated with schizophrenia 
while the latter producing more of the “secondary” effects such as visual and auditory hallucinatory 
events.49 Moreover, PCP was shown to exacerbate and reinforce preexisting psychotic symptoms 
in schizophrenia patients and produced symptoms in acute schizophrenic patients.49 PCP was 
first found to antagonize the excitatory effects of the NMDA channel (for which L-glutamate is the 
endogenous neurotransmitter) in the vertebrae of rats and cats.50 Furthermore, it was found that 
PCP binds at a distinct site relative to L-glutamate, thus producing its antagonism through a 
noncompetitive manner.51,52 Glutamate is known to be important for learning and memory, 
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processes that are dependent on glutamate’s ability to induce hippocampal long-term potentiation 
(LTP) which is related to synaptic plasticity. Lastly, a specific subunit (NR2A) of NMDA receptors 
is downregulated in GABAergic neurons of schizophrenia brains and disruptions in the modulation 
of GABA have also been linked to schizophrenia.53 Together, with the results of research with 
PCP and the physiological role of glutamate, it can be postulated that glutamate and its excitatory 
effects are crucial to maintaining healthy cognition and disruptions in its effects (antagonism) can 
produce behavioral effects similar to the psychotic symptoms of schizophrenia. 
 
4. GABA hypothesis of schizophrenia: As opposed to glutamate, which is an excitatory 
neurotransmitter, gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in 
the mature central nervous system, effecting its inhibition on pyramidal neurons located in the 
hippocampus, cerebellum, thalamus, and neocortex (based on GABA-A receptor channel isoform 
and GABAB1/GABAB2 receptor distribution),54,55 all areas of the brain affected by schizophrenia. 
In contrast, GABA has been shown to act as an excitatory neurotransmitter in the developing 
brain.56 Disruptions in both the excitatory and inhibitory neural transmission of glutamate have 
been implicated in the pathogenesis of schizophrenia.57,58 GABA is synthesized in GABAergic 
presynaptic neurons where glutamate is decarboxylated by glutamic acid decarboxylase (GAD) 
to form GABA. It is then packaged into vesicles by the vesicular GABA transporter (VGAT) and is 
released into the synapse to bind at GABA receptors A and B upon depolarization of the 
membrane, after which its signal is terminated in part due to reuptake by the glutamate transporter 
(GAT).58 It has been reported that mRNA of GAD67, the enzyme responsible for maintaining basal 
levels of GABA, is significantly reduced in layers 3, 4 and 5 of the prefrontal cortex but is largely 
unaffected in most GABAergic neurons in postmortem brains of schizophrenia patients.59 This 
reduction of GAD67 levels is directly correlated with the reduction of the mRNA of parvalbumin,60 
an enzyme found in subsets of GABAergic neurons characterized by their high rate of firing action 
potentials, which might imply that the reduction in the levels of GAD67 mRNA is specific to a 
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subset of GABAergic neurons containing the enzyme parvalbumin.61 There is also evidence for 
the reduction of GAT-1 mRNA levels,62,63 a subset of GABA transporters that are responsible for 
the majority of GABA modulation, and also for the reduction of the 2 subunit of GABAA type 
receptor, a subunit found on a vast majority of pyramidal neurons synapsed by GABAergic 
neurons, in postmortem schizophrenia brains. This would suggest that the schizophrenia is 
associated with a reduction of GAT-1 and a subset of GABAA receptors and as a result of an 
increase in the level of GABA and inhibition of postsynaptic neurons. This is in contrast to the 
increased excitation that would result from a reduction GAD67 and therefore a reduction of GABA 
synthesis, suggesting that schizophrenia is characterized by hypofunction of both the excitatory 
and inhibitory pathways of GABA. Others have reported downregulation of several other GABAA 
receptor subunits including 1, 4, 5, 2, and . These results illuminate the complex and multi-
faceted relationship between GABAergic neurotransmission and schizophrenia.  
C. Antipsychotic Drugs 
Prior to the 1950s, treatment of schizophrenia was limited to crude methods such as 
electroconvulsive therapy, treatment with nonspecific sedatives such as morphine, opium, and 
codeine, physical restraint, and administration of insulin.64,65 It wasn’t until the discovery of 
chlorpromazine (3), a phenothiazine derivative originally used as part of a sedative concoction  in 
surgery,66 and reserpine (4) (Figure 5), originally used as a antihypertensive,67 that research into 
the treatment of psychosis started to look promising. These discoveries spawned what is known 
as the “psychopharmacological revolution”64 after both drugs were found to be efficacious in the 
alleviation of psychotic symptoms in schizophrenic patients through their tranquilizing effects and 
became widely used clinically.67,68 Their use clinically encouraged researchers to investigate the 
pharmacological action of these drugs and they found a dopaminergic component to 
chlorpromazine40 and a serotonergic component to reserpine.69 Discovery of other antipsychotic 
drugs soon followed including haloperidol (5), thiothixene (6), thioridazine  (7), and trifluoperazine 
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(8) (Figure 5), among others, which formed a class of drugs known as typical antipsychotic drugs 















Figure 5. Structure of typical antipsychotic drugs chlorpromazine (3), reserpine (4), haloperidol 
(5), thiothixene (6), thioridazine (7), and trifluoperazine (8). 
The problems with typical antipsychotic drugs are that they result in high incidences of 
extrapyramidal stimulation (EPS) symptoms related to primary antagonism of D2 receptors,70 such 








apathy and lack of motivation.65 In the 1970s, the dibenzodiazepine antipsychotic clozapine (9) 
(Figure 6) was discovered and was shown to be very effective clinically in treating schizophrenia, 
including the negative symptoms, and did not produce EPS symptoms. Drugs exhibiting these 
characteristics became known as atypical antipsychotic drugs, display 5-HT2A/D2 receptor 
antagonism,70 and later included drugs discovered in the 1990s risperidone (10), olanzapine (11), 
sertindole (12), and quetiapine (13) (Figure 6).66 The latter group of drugs were essential because 










Figure 6. Structure of atypical antipsychotic drugs clozapine (9), risperidone (10), olanzepine 











D. 5-HT2A Receptor Antagonist Pharmacophore 
Since the discovery of atypical antipsychotic drugs, numerous studies have been 
conducted in an attempt to understand the structure-activity-relationship (SAR) of these drugs71–
73 to further increase their efficacy and decrease their incidence of EPS. One particular area of 
interest is in the pharmacophoric evaluation of risperidone (10) (Figure 6) at 5-HT2A receptors.74–
77 Risperidone was chosen for examination because it is used clinically and maintains a high 
affinity and potency at 5-HT2A receptors (Ki = 5.29 nM and IC50 = 5.59 μM, respectively).76  Our 
group has previously published results of a deconstruction study of risperidone in order to 
determine its minimal structural features necessary (pharmacophore) for antagonism of 5-HT2A 
receptors.76,77  
Developing a pharmacophore for a receptor is a highly illuminating method for rational 
drug design. This method usually involves the deconstruction step of the Deconstruction, 
Reconstruction, Elaboration (DRE) approach, first established by Glennon.78 In this step, a 
molecule is stripped down to determine essential substituents for activity. In the reconstruction 
step, the molecular scaffold is synthesized containing only these essential substituents and 
omitting nonessential ones. In the elaboration approach, substituents are added to the molecule 
in a rational way (usually incorporating the Craig Plot or Topliss Tree methods) to optimize 
activity.78 
5-HT2A receptors were the focus in this study because a reduction of EPS symptoms of 
atypical antipsychotic drugs is correlated with greater 5-HT2A activity and lower D2 activity and so 
a greater understanding of the structural requirements for antagonism of 5-HT2A receptors might 




A typical pharmacophoric model for 5-HT2A antagonism based on the structural 
requirements and distance investigations of 5-HT2A ligands by various groups79–82 is shown in 
Figure 7 (as summarized by Younkin et al.76) which consists of two aromatic centers separated 
by given distances from a basic nitrogen atom. The initial deconstruction of risperidone conducted 
by our laboratories revealed that the entire structure of risperidone is not required for antagonism 
at 5-HT2A receptors, a result corroborated by the comparable antagonist actions of compounds 
14 (Ki = 71.41 nM; IC50 ± 2.24 μM) and 15 (Ki = 12.27 nM; IC50 = 7.40 ± 1.45 μM) to that of 
risperidone. In particular, only one aromatic center might be required for antagonist activity. 
Figure 7. Composite of pharmacophoric model developed by various groups.76 
 
 
Figure 8. Structure of abbreviated compounds 14 and 15. 
In a more comprehensive deconstruction analysis of risperidone (10) and ketanserin (16) 
(Figure 9) by our group, Shah et al. examined several deconstructed analogues of risperidone 
(5.29 nM and 5.59 μM at 5-HT2A receptors) and ketanserin (Ki = 15.5 nM, IC50 = 32.4 μM at 5-












deconstructed by removing the 6-fluoro substituent on the benzisoxazole ring. The des-fluoro 
analog of 14 retained nanomolar affinity and micromolar potency (Ki = 271 nM and IC50 = 3.49 
μM), showing that, although beneficial for activity, the 6-fluoro substituent is not essential. The 
results of this study were utilized to revise the existing pharmacophoric model for 5-HT2A 
antagonism producing the model shown in Figure 10.  
 
Figure 9. Structure of ketanserin. 
 
Figure 10. Revised pharmacophoric model for 5-HT2A antagonism.77 
In the initial deconstruction study, results indicated that only the “right half” portion 
(benzisoxazole/piperidine-containing portion) of risperidone (10) is necessary for antagonist 
action at 5-HT2A receptors. This might suggest that the binding of this portion might be magnified 
by the presence of the “left half” portion (pyrimidinone-containing moiety). To test this hypothesis, 




risperidone and the right or left portions of ketanserin. Agents containing only the left half portion 
of risperidone did not have appreciable affinity for 5-HT2A receptors (Ki ≥ 5,000). However building 
onto these agents by adding the right half portion of ketanserin (16) as seen in Figure 11 produces 
a compound (17) with greater affinity and potency than ketanserin (Ki = 3.02 nM and IC50 = 25.7 
μM). The other hybrid compound containing the left half portion of ketanserin (16) and the right 
half portion of risperidone (10) (Figure 6) 18 displayed greater affinity and potency (Ki = 0.37 nM 
and IC50 = 0.7 μM) than either risperidone or ketanserin. It was also revealed that a tertiary amine 
is optimal for binding i.e. the piperidine nitrogen atom of risperidone. These results reveal multiple 
insights with regard to the structure-activity relationships of risperidone antagonism at 5-HT2A 
receptors.  
 
Figure 11. Structure of hybrid molecules with the “left half” portion of risperidone and the “right 
half” portion of ketanserin (17) and the “right half” portion of ketanserin and the “left half” portion 
of risperidone (18). 
 
E. Significance of 5-HT2B Receptors 
Although 5-HT2B receptors are generally considered to be anti-targets due to the 
prevalence of cardiac valvulopathic effects precipitated by their activation, the study of these 
receptors is still very crucial for drug development. Early studies reported that high levels of 
serotonin excreted into the blood stream by carcinoid tumors result in fibrosis of particular heart 




SSRIs are associated with abnormal heart function including arrhythmias, bradycardia, atrial 
fibrillation, and tachycardia.85 Despite this, there is evidence for 5-HT2B receptors being implicated 
in the therapeutic action of SSRIs with one group showing that the response of mice (i.e., mobility) 
in the forced swim test (FST) is absent in 5-HT2B-/- mice86 and later showing that these mice fail 
to respond to long-term administration of SSRIs in a novelty-suppressed feeding test.87 However, 
focus has remained on the heart abnormalities that result upon activation of this receptor and 5-
HT2B receptors in particular have been linked to the shape and morphology of the heart, with one 
group reporting a reduction of ventricular mass in 5-HT2B receptor mutant mice.88 Furthermore, a 
later study reported that overexpression of 5-HT2B receptors in the heart leads to cardiac 
hypertrophy in mice.89 The research into the link between 5-HT2B receptor activation and cardiac 
dysfunction has led those in the field to investigate the possible therapeutic uses of 5-HT2B 
antagonists. One group demonstrated that administration of 5-HT2B antagonists SB204741 and 
terguride diminishes induced right ventricle fibrosis following pulmonary artery banding (PAB) 
treatment in mice.90 
Studies with fenfluramine (19) (Fen, Figure 12), a 5-HT2B agonist, prompted extensive 
research into the relationship between 5-HT2B receptors and cardiac abnormalities. Fen was 
initially prescribed as an anti-obesity drug in 1973, but was removed from the market in 1997 due 
to occurrences of cardiac disorders, specifically cardiac valvulopathy and pulmonary 
hypertension, in patients.91,92 The cardiac valvulopathy associated with Fen has been 
characterized by thickening of the aortic, mitral, and tricuspid valves with plaque-like deposits 
along the leaflets and chordae tendineae, as well as regurgitation of blood through the valves.92 
These symptoms are similar to those seen in patients with carcinoid valve disease.92 Fen and its 
metabolites act as both 5-HT2B agonists and serotonin releasers at serotonin transporters 
(SERT).93 However, the mitogenesis associated with the cardiac valvulopathic effect is thought to 
be precipitated by the downstream action of Gq-mediated activation and beta arrestin recruitment 
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rather than serotonin release;94 in fact, Fen was actually found to decrease platelet and plasma 
levels in both humans and animals.95–97 The popular street drug MDMA (or 3,4-
methylenedioxymethamphetamine, also a 5-HT2B receptor agonist), produces significant 
mitogenic changes in human heart valve interstitial cells and valvular regurgitation and 
morphological changes in patients.98,99 Administration of other 5-HT2B receptor agonists such as 
anti-Parkinsonism drugs, pergolide and cabergoline, induces cardiac valve regurgitation in 
patients.100 These results provide further evidence for the association between the activation of 
5-HT2B receptors and the incidence of cardiac valvulopathy.  
 
Figure 12. Structure of fenfluramine (Fen; 19) and its active metabolite norfenfluramine (nFen; 
20). 
Despite its adverse cardiological effects, Fen is a very effective anorectic101,102 shown to 
result from 5-HT2C receptor activation,103,104 and was very popular when available on the market 
(5 million US patients used prescription Fen between 1996-1998).98 Fen has recently been 
reevaluated for the treatment of Dravet’s syndrome and is currently in clinical trials. A low dose of 
Fen significantly diminished epilepsy-associated seizures, with patients experiencing freedom 
from seizures in as little as 3 days and a median reduction in seizure frequency of 80%.105 The 
antiepileptic effect of Fen is thought to be precipitated through action at 5-HT1D, 5-HT2A, 5-HT2C, 
and sigma-1 receptors.105–108 Fen clearly has therapeutic potential and structural modification to 
abolish its affinity for 5-HT2B receptors (and thus its adverse cardiac effects) can open the door to 
more effective treatment options without dangerous side effects. 
Fen (19) nFen (20) 
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Fenfluramine’s most active N-deethylated metabolite is norfenfluramine (nFen, 20) (Figure 
12), which has much higher affinity and functional activity at 5-HT2B receptors (Table 1). (±)nFen 
has an affinity of over 79-fold greater than that of (±)Fen, which also corresponds with almost two-
fold greater Vmax values of the isomers of nFen relative to those of Fen. This effect is also seen 
with regard to 5-HT2A receptors at which fenfluramine/norfenfluramine and their metabolites 
posess greater affinity and functional activity. Considering the greater activity of nFen compared 
with Fen at 5-HT2B receptors, it is believed that the majority of 5-HT2B activation and thus induction 
of cardiac valvulopathy that occurs upon Fen administration is due to the action of nFen and not 
Fen.93 Both nFen and Fen belong to a class of compounds known as phenylisopropylamines. 



















(% of 5-HT 
response; PI 
hydrolysis) 
(±)Fen 5216 4134 15 ND 
(+)Fen 11107 5099 ND 38 
(-)Fen 5463 5713 43 47 
(±)nFen 2316 52.1 ND ND 
(+)nFen 1516 11.2 88 73 










Phenylisopropylamines can have a broad range of activities from stimulant effects as seen 
with amphetamine110 to hallucinogenic effects as seen with classical hallucinogens in the DOX 
series (Table 2),111,112 to anorectic effects as seen with fenfluramine (19).102 The Ar-C-C-N (aryl-
carbon-carbon-nitrogen) moiety contained in the phenylisopropylamine scaffold is so common in 
a wide variety of drugs because they resemble neurotransmitters containing the same moiety 
(e.g. serotonin, dopamine, norepinephrine) with which they might share the same target 
proteins.113 The simplest version of a related class of compounds is phenethylamine (Figure 13) 
(43) which has no substituents on its phenyl ring or its alkyl chain. Phenethylamine is not known 
to produce significant central stimulating effects upon administration; however, adding an -
methyl substituent, forming amphetamine (42) (Table 2) (a phenylisopropylamine), adds a central 
stimulant component to the drug.113 With regard to phenylisopropylamine hallucinogens, 
mescaline is the prototypical phenethylamine compound.114 Modification of its structure by 
addition of an -methyl substituent results in the phenylisopropylamine trimethoxyamphetamine 
(TMA; 38) (Table 2). Shulgin, later, after investigating a series of substitution patterns of TMA, 
concluded that the 2,4,5-methoxy substitution pattern was optimal in terms of hallucinogenic 
activity as seen with TMA-2 (27) (Table 2).112 It should be noted that although the -methyl 
substituent distinguishes phenethylamines from phenylisopropylamines, the -methyl does not 
seem to improve the affinity101 or efficacy115 at 5-HT2A receptors in vitro. However, an improvement 
is seen in the ED50 values of phenylisopropylamines vs. phenethylamines in drug discrimination 
assays as represented by the lower ED50 value of DOM (25) (ED50 = 1.8 μmol/kg) than of its des-
-methyl counterpart 2C-D (44) (Figure 13) (ED50 = 5.6 μmol/kg). One reason for this effect is that 
the -methyl substituent may be adding lipophilic character to the compound and thus is able to 
cross the blood-brain barrier (BBB) more effectively to exert its central effects. 
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Figure 13. Structures of phenethylamine (43) and 2C-D (44). 
Compound Name R1 R2 R3 R4 R5 R6 
21 DOF  NH2 OCH3 H F OCH3 H 
22 DOB NH2 OCH3 H B OCH3 H 
23 DOI NH2 OCH3 H I OCH3 H 
24 DOC NH2 OCH3 H Cl OCH3 H 
25 DOM NH2 OCH3 H CH3 OCH3 H 
26 2,5-DMA NH2 OCH3 H H OCH3 H 
27 TMA-2 NH2 OCH3 H OCH3 OCH3 H 
28 MEM NH2 OCH3 H OCH2CH3 OCH3 H 
29 DOAc NH2 OCH3 H COCH3 OCH3 H 
30 DON NH2 OCH3 H NO2 OCH3 H 
31 DOCN NH2 OCH3 H CN OCH3 H 
32 DOPR NH2 OCH3 H Propyl OCH3 H 
33 DOHx NH2 OCH3 H Hexyl OCH3 H 
34 DOTB NH2 OCH3 H t-Butyl OCH3 H 
35 DOBz NH2 OCH3 H Benzyl OCH3 H 
36 DOCT NH2 OCH3 H Octyl OCH3 H 
37 DOPP NH2 OCH3 H 3-(Phenyl)propyl OCH3 H 
38 TMA NH2 H OCH3 OCH3 OCH3 H 
39 M-154 N(CH3)2 OCH3 H Br OCH3 H 
40 D-367 NH-C3H7 OCH3 H Br OCH3 H 
41 QDOB N+(CH3)3 OCH3 H Br OCH3 H 
42 Amphetamine NH2 H H H H H 
 
β 
Phenethylamine (43) 2-CD (44) 
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Phenylisopropylamines have chiral centers at the -carbon and the R(-) enantiomers are 
generally the most potent agonists at 5-HT2A receptors (fenfluramine/norfenfluramine and 
metabolites being exceptions). Glennon et al. investigated the additions of hydroxy and methoxy 
substituents to the β position of 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane DOB (Table 
2) (22), the brominated analogue in the DOX series of hallucinogens.116 β-Hyroxylation and β-
methoxylation, forming new chiral centers with the designation 1R,2R is well tolerated and 
produces compounds with similar affinities and efficacies as DOB at 5-HT2A receptors. However, 
the 1R,2R, β-methoxylated compound is the only one that has a significantly higher potency as 
compared with DOB (almost 2-fold). 
Greater interest in phenylisopropylamine hallucinogens prompted researchers to 
determine the ideal substitution of methoxy substituents with regard to affinity and efficacy. It was 
revealed that the 2,5-dimethoxy pattern is best tolerated.117 Glennon et al. further reported that 
substitution of the 2-methoxy substituent with a 2-hydroxy substituent in DOM (Table 2) (25) 
produced similar behavioral responses in drug discrimination assays but this same tolerance was 
not seen with substitution of the 5-methoxy substituent.117 In the same study, it was further 
revealed that removal of the 4-position methyl substituent followed by addition of a methyl 
substituent at the 3-position failed to produce the same behavioral responses as DOM, indicating 
that a substituent at the 4-position is necessary for hallucinogenic-like activity in animals. This 
effect is corroborated by the result that DOM displays ten times the potency of TMA-2 (27), also 
indicating that a hydrophobic substituent at the 4-position might improve the activity of this 
series.118  Glennon et al. reported in a later study involving DOB that both the 2- and 5-position 
methoxy substituents are necessary for 5-HT2A binding, and removal of the former results in 
complete abolishment of affinity.119 Demethylation of the 2-methoxy substituent results in a 3-fold 
reduction in 5-HT2A affinity. Alkylation of the terminal nitrogen via addition of a propyl substituent 
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drastically reduced affinity by about 30-fold, indicating that alkyl substituents on the terminal 
amine are not very well tolerated.119 
As mentioned earlier, hydrophobic substituents at the 4-position of phenylisopropylamines 
seem to be beneficial for activating 5-HT2A receptors. Glennon and coworkers118 examined a 
series of analogues with variation of substituents at the 4-position of 2,5-DMA (26) (Table 2) with 
polar and hydrophobic substituents and found that polar substituents dramatically reduced the 
affinity at 5-HT2A receptors with carboxy, hydroxy, and amino substituents displaying the lowest 
affinity (Ki > 25,000 nM). Lipophilic substituents on the other hand (alkyl or branched alkyl groups) 
were very well tolerated. Halogen substitution showed that the bromo substituent is the most 
favorable (Ki = 41 nM), followed by the chloro substituent (Ki = 218 nM), followed by the fluoro 
substituent (Ki = 1100 nM). Furthermore, two of the high affinity ligands (4-t-Bu and 4-pentyl 
analogs) were found not to generalize to DOM in drug discrimination and so were suspected of 
being antagonists. Four compounds, 4-hexyl (i.e., 33) (DOHx), 4-benzyl (i.e., 35) (DOBz), 4-octyl 
(i.e., 36) (DOCT), and 4-[3-(phenyl)propyl] (i.e., 37) (DOPP) (Table 2) analogues, were evaluated 
in an isolated tissue assay in rat thoracic aorta to test for agonist activity and all four were found 
to be antagonists.118 This result raised the possibility of producing 5-HT2A antagonists by the 
addition of bulk at the 4-position of phenylisopropylamines. 
Although much research has involved developing structure-activity-relationships (SAR) of 
phenylisopropylamines, much more data are needed to fully characterize this class of 
compounds. For example, although there are numerous reports for the 5-HT2A affinity data for this 
class, their functional activity at 5-HT2A receptors has been limited to a relatively few compounds, 
e.g., DOI, DOB, DOM, DON, 2,5-DMA, and TMA.120–122 Glennon, et al. has also conducted PI 
hydrolysis studies and provided intrinsic efficacy values for a series of DOX analogues and 
positional isomers of TMA.123 A comprehensive affinity analysis for a series of DOX compounds 
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at 5-HT2A and 5-HT2B receptors has been conducted by Nelson et al.111 but a greater degree of 
functional data at these receptors, especially 5-HT2B, is still needed for these analogues. 
Table 3.  Affinity values of a series of DOX compounds at 5-HT2A and 5-HT2B receptors.111 
Compound Name 
5-HT2A Ki[nM]  
 [125I]DOI 
5-HT2B Ki[nM]  
[3H]5-HT 
21 DOF 41.7 227 
22 DOB 0.6 26.9 
23 DOI 0.7 20.0 
24 DOC 1.4 31.8 
26 2,5-DMA 211 1039 
27 TMA-2 57.9 307 
28 MEM 73.0 763 
29 DOAc 80.5 313 
30 DON 5.5 166 
31 DOCN 45.7 774 
32 DOPR 0.9 54.4 
33 DOHx 0.1 30.3 
34 DOTB 3.7 24.6 
35 DOBz 0.4 35.0 
39 M-154 94.2 341 
40 D-367 88.5 521 




Quipazine (45) (Figure 14) is considered to be an enigmatic 5-HT2A receptor agonist 
because it does not share the structural scaffold common to classical hallucinogens such as the 
tryptamine, phenethylamine, or ergoline scaffolds and instead contains an arylpiperazine scaffold. 
Despite this, quipazine binds at 5-HT2 receptors and produces behavioral effects in drug 
discrimination124 and head-twitch response (HTR)125 assays similar to those of classical 
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hallucinogens, However, it is unknown if quipazine is hallucinogenic because human data are 
limited to anecdotal evidence.126 
 
Figure 14. Structures of quipazine (45) and its structural analogues isoquipazine (46), 2-NP 
(47), and 1-NP (48). 
Originally developed having antidepressant implications, quipazine was found to 
antagonize the sedative effects of reserpine and tetrabenazine (similar to the clinically used 
antidepressant imipramine) and inhibited the mouse-killing behavior of rats, effects that were 
thought to be indicators of potential antidepressant activity.127 However, in the same study it was 
revealed that quipazine had no effect on the inhibition of monoamine oxidase (MAO) nor on the 
uptake of norepinephrine or serotonin, which were known to be the mechanisms of 
antidepressants until that point. Subsequent studies with quipazine in drug discrimination assays 
revealed that quipazine can generalize to the response of LSD in rats trained to discriminate LSD 
from saline.128 Similarly, rats trained to discriminate between quipazine and saline recognized the 
LSD cue, an effect that was blocked by 5-HT antagonists cyproheptadine, methysergide, and 
methiothepin but not dopamine antagonists fluphenazine and haloperidol.129 Together these 
results indicated that, like LSD, quipazine might have a serotonergic component to its behavioral 
effects.  
Quipazine (45) 1-NP (48) 2-NP (47) Isoquipazine (46) 
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Other compounds in the same class (arylpiperazine) as quipazine are 1-(3-
trifluoromethylphenyl)piperazine (TFMPP) (49) and its chloro analogue 1-(3-
chlorophenyl)piperazine (mCPP) (50) (Figure 15), both of which are agonists at various serotonin 
receptors. Animals trained to recognize TFMPP in drug discrimination assays generalized to the 
mCPP cue. However, this effect is not seen with quipazine. Instead quipazine generalizes to DOM 
(and LSD as mentioned earlier), a compound with known 5-HT2A receptor agonist activity, 
indicating that the action of quipazine is through 5-HT2A receptors unlike TFMPP and mCPP.124 
The similarities of the effects of quipazine to hallucinogens such as LSD and DOM is 
understandable considering the similarities in their structural scaffolds: they all contain a 




Figure 15. Structures of TFMPP (49) and mCPP (50). 
Quipazine binds with nanomolar affinity at 5-HT2A receptors as reported by multiple 
laboratories (Table 4). However, there are discrepancies in the binding affinity of quipazine which 
depend on the radioligand used in the assays. For example, quipazine binds with lower affinity at 
5-HT2A receptors labeled with the antagonist [3H]-ketanserin, compared to when agonists [125I]-
DOI or [3H]-DOB are used as radioligands (~4-26x lower). This is consistent with literature data 
showing that agonists such as 5-HT, DOI, and quipazine and partial agonist mCPP display higher 
affinities at 5-HT2A receptors radiolabeled with [3H]-DOB (~2-8x higher) than at 5-HT2A receptors 
radiolabeled with [3H]-ketanserin.130 This same effect is not observed with antagonists spiperone, 
mesulergine, and ketanserin. Literature also shows that [3H]-ketanserin binds to a much higher 
population of receptors than [125I]-DOI in both brain tissue and HEK-293 cell preparations.131,132 
TFMPP (49) mCPP (50) 
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Although binding assay calculations are conducted by accommodating for nonspecific binding, 
the higher amount of agonist needed to displace [3H]-ketanserin at a higher population of 5-HT2A 
receptors might factor in to the higher affinity of agonists at [3H]-DOB/[125I]-DOI labeled 5-HT2A 
receptors than at [3H]-ketanserin labeled receptors. 
Table 4. Comparison of binding affinities of quipazine (45), 2-NP (47), isoquipazine (46), and 1-
NP (48) at 5-HT2A receptors using radioligands [3H]-ketanserin, [125I]-DOI, and [3H]-DOB across 
human, mouse, and rat species. 
 Quipazine Ki 
[nM] 
2-NP Ki [nM] 
Isoquipazine 
Ki [nM] 
1-NP Ki [nM] 
[3H]-Ketanserin,       
h5-HT2A 














[3H]-Ketanserin,       
h5-HT2A 
362133 NA NA NA 




70124 NA 18124 
[125I]-DOI, h5-HT2A 129132 NA NA NA 
[125I]-DOI, h5-HT2A 5131 NA NA NA 




NA NA NA 
*Average data collected from PDSP Ki database. bNA = unavailable; not reported. 
Very few SAR studies have been conducted on quipazine’s action at 5-HT2A receptors. In 
one study by Glennon et al.124 quipazine and its structurally related analogues including 1-NP (46) 
and 2-NP (47) (Figure 14) were assessed in radioligand binding and drug discrimination assays. 
2-NP (Ki = 70 nM) displayed a higher affinity at 5-HT2A receptors than quipazine (Ki = 230) and 
achieved greater selectivity for 5-HT2 over 5-HT1 receptors. 1-NP displayed an even higher affinity 
for 5-HT2A receptors (Ki = 18 nM) but was not selective for 5-HT2A. These results indicate that the 
quinoline nitrogen atom of quipazine is not necessary for activity and might even diminish its 
affinity for 5-HT2A receptors; this might be due to some electrostatic clash with amino acids in the 
binding site. Furthermore translocation of the piperazine ring from the 2-position to the 1-position 
30 
 
of the naphthalene ring of 2-NP (as seen in 1-NP) is more favorable for binding. In drug 
discrimination assays, animals were trained using either TFMPP or DOM as the stimulus drug. It 
was found that the DOM stimulus generalized to 2-NP but not to 1-NP and the TFMPP stimulus 
generalized to 1-NP but not to 2-NP;124 1-NP has been shown to be a 5-HT2A receptor 
antagonist.124,125 Several other compounds were also investigated to understand the SAR of 
quipazine. Through these compounds it was demonstrated that the 4-position nitrogen atom of 
quipazine (i.e., N4) is essential and an 8-methoxy substituent on the quinoline ring of quipazine is 
tolerated with respect to binding at 5-HT2A receptors. 
Quipazine also displayed very high affinity (Ki = 1.5 nM)140 and potent antagonism of 5-
HT3 receptors141 and [3H]quipazine was used to label 5-HT3 recognition sites in rat cortical 
membranes.142 5-HT3 receptor channels are implicated in the functioning of the gastrointestinal 
tract in actions such as release of gastrointestinal (GI) secretions, control of vomiting, peristalsis 
as well as in the modulation of GI disorders such as gastroesophageal reflux disease and irritable 
bowel syndrome. In the few anecdotal reports126 of quipazine’s effect in humans, patients reported 
GI disturbances, diarrhea, vomiting, and “low dose mescaline-like effects” and similar effects were 
seen in monkeys except they exhibited behavior as seen upon administration of LSD, indicating 
that the hallucinogenic effects were stronger in monkeys than in humans. These observations 
have raised questions regarding the hallucinogenic action of quipazine. Specifically, it has been 
proposed that a higher dose of quipazine might produce hallucinogenic experiences in humans if 
it were not for the accompanying higher incidences of GI disturbances. Thus, administration of an 
antiemetic such as ondansetron prior to quipazine might allow users to consume a high enough 
dose of quipazine to experience its hallucinogenic action.126 Additionally, pretreatment with 
ondansetron significantly reduced the fecal count of mice given quipazine.125 Furthermore, 
pretreatment with ondansetron in mice administered quipazine in the HTR assay had no 
significant effect on the HTR counts revealing that the behavioral effects of mice in the HTR assay 
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by quipazine is not linked with its agonism at 5-HT3 receptors.125 Regardless of these indications, 
published data from studies with human subjects consuming quipazine are required to definitively 




















III. Specific Aims and Rationale 
5-HT2A and 5-HT2B serotonin receptors share high sequence identity (39.96% - UniProt 
Allignment Data), especially in their respective ligand binding sites and transmembrane regions 
(Figure 16). They both contain a highly conserved aspartic acid amino acid in transmembrane 3 
(TM3), a residue that is conserved across all aminergic GPCRs.143–145 This residue serves as an 
anchor point for ligands of 5-HT2A and 5-HT2B receptors by forming salt bridge interactions (i.e. 
ionic bonds) between its negatively charged oxygen atoms and the positively charged amines of 
ligands. Agonists of both receptors interact with specific residues that share similar positions in 




























Figure 16. Sequence alignment of human 5-HT2A and 5-HT2B receptor sequences. Blue regions 
highlight sequence identity and red regions highlight transmembrane regions. 
The similarities in the binding and activation of ligands binding at 5-HT2A and 5-HT2B 
receptors can be clearly elucidated by comparing bound crystal structures of the agonist LSD at 
both receptor subtypes, published by Roth and collegues while our investigation was in 
progress.146–148 Their results indicated that LSD interacts with similar residues and only displays 
slight differences in the binding site of both receptors. These interactions include hydrophobic  

























5-HT2A and Phe3406.51 and Phe3416.52 in 5-HT2B). In TM5 LSD (2) hydrogen bonds with S2425.46 
in 5-HT2A receptors. An analogous residue Ala2255.46 at the same position in 5-HT2B receptors 
was shown to be essential for agonism in studies with agonist methylergonovine.146 Along with 
binding similarities, LSD displays similarities in its kinetic and pharmacological activity at 5-HT2A 
and 5-HT2B receptors. LSD displays relatively slow dissociation rates at both receptors (koff = 
0.003 ± 0.0005 min-1 and 0.022 ± 0.004 min-1, respectively).147,148 It has been proposed that this 
effect is caused by residues in extracellular loop 2 (EL2) forming a “lid” in the binding sites of both 
5-HT2A and 5-HT2B receptors, preventing LSD from dissociating. Specific residues such as 
Ser2425.46 and Leu229EL2 in 5-HT2A and Leu209EL2 in 5-HT2B have been implicated in the slow 
kinetics exhibited by LSD, as supported by mutagenesis studies. Additionally, LSD displays β-
arrestin recruitment along with G-protein activation at both receptors. LSD’s similarity in both 
binding and pharmacological activity at 5-HT2A and 5-HT2B receptors adds credence to the 
difficulty in separating activity at these receptor subtypes. This is the reason why pharmacological 
efforts are underway for developing pharmacophores for both receptors. Determining the 
minimum structural features necessary for activity at these receptors can assist in the design of 
more selective ligands. 
Initial investigation into the pharmacophoric implications for 5-HT2A functional activity was 
conducted by Hӧltje et al.81 following Glennon et al.’s affinity SAR studies of a series of 
phenethylamine/phenylisopropylamine (discussed earlier) and indolalkylamine derivaties.149 
Hӧltje and co-workers revealed through conformational analysis using crystal structures of 
different isomers of phenylisopropylamines and indolalkylamines, that specific isomers might elicit 
more potency due to possible spatial accommodation limitations in the binding site for the -alkyl 
substituent. The most important finding of this study was that a specific distance between the six-
membered aromatic ring and the basic nitrogen (5.2 Å) is necessary for the agonist activities of 
the compounds examined. Since then, conformational analyses and computational modeling 
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such as CoMFA and 3D-QSAR conducted by several groups,79,82,150–152 revealed structural 
overlap between agonists and antagonists as well as structural requirements for the binding of 
antagonists. These requirements include two aromatic center moieties separated by given 
distances from a basic nitrogen atom as summarized in Figure 7. Since these studies, Shah et 
al.77 have refined this model using a sophisticated DRE approach and produced the 
pharmacophoric model seen in Figure 10. As mentioned in the background regarding the history 
of the development of antipsychotic drugs, EPS symptoms result from excessive D2 receptor 
antagonism and so reducing the D2 component (and increasing the 5-HT2A antagonist component) 
has been the focus in the further development of atypical antipsychotic drugs. In the elaboration 
step of the DRE evaluation of risperidone, substituents can be added to the deconstructed 
pharmacophoric structure 14 to form new compounds. Determination of their activity across 
multiple receptor types, e.g., 5-HT2A-2C, D1-5, 1A, and 1B receptors, can reveal what structural 
features might confer selectivity for 5-HT2A receptors. These receptors were chosen because 
atypical antipsychotic drugs have been hypothesized and/or shown to display activity at a variety 
of serotonin receptors, dopamine receptors, and adrenergic receptors.153 These insights, in turn, 
can assist medicinal chemists in designing more effective therapeutics for schizophrenia (through 
improved, selective 5-HT2A antagonism). 
Pharmacophoric exploration of 5-HT2B receptors has been much more limited than of 5-
HT2A receptors. Multiple researchers have performed SAR studies to produce selective 
antagonism at 5-HT2B receptors154–156 and one group has developed a broad antagonist 
pharmacophore model (Figure 17) consisting of lipophilic/aromatic centers and hydrogen bonding 
donor/acceptor moieties,156 similar to the model produced for 5-HT2A antagonism as seen in 
Figure 7. However, these studies failed to define one of the hallmarks of pharmacophoric analysis 
that is the minimum structural features necessary to elicit an effect. Instead high-throughput 
screening was used to determine hits and minor modifications were made to selected compounds 
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in order to develop selective and effective compounds, i.e., a thorough deconstruction analysis 
was not performed. The development of a selective antagonist for receptors is generally a less 
demanding method than developing selective agonists because of engagement of auxiliary 
binding sites not engaged by agonists. Because of this, antagonists can bind in a manner that is 
very specific to its receptor, thereby conferring high selectivity. This can also result in the loss of 
application of the pharmacophoric insights to antagonists with other scaffolds, as the insights 
might be specific to the evaluated class of compounds containing a unique scaffold. Research 
into the pharmacophoric requirements of 5-HT2B agonism has been essentially nonexistent, 
although it could greatly expand on the methods to reduce 5-HT2B-induced cardiac valvulopathy. 
Some groups, e.g. Roth and colleagues,146 have attempted to determine specific structural 
features of ligands necessary for activation and functional selectivity using specific classes of 
compound such as ergolines. Several insights were made with respect to the activity of these 
compounds, however the same issue, as mentioned above, holds true in these studies: extensive 
deconstruction analyses were not performed to determine the minimal structural features 



















Figure 17. Broad 5-HT2B antagonist pharmacophore consisting of hydrophobic regions (yellow), 
ionizable groups (blue), and hydrogen bond donors (green).156 
Because of the high sequence homology between 5-HT2A and 5-HT2B receptors (60% in 
rats),157 the binding affinities of the series of compounds in Table 3 show strong correlation 
between these receptors as seen in Figure 18. It would be interesting to conduct similar correlation 
analyses between functional activity and affinity for this series at 5-HT2A receptors to test the 
capability of affinity to predict functional activity and vice versa. The same should be done with 5-
HT2B and additional correlations should be developed correlating the functional activity of 
compounds at 5-HT2A receptors with their functional activity at 5-HT2B receptors to determine 
which structural features are unique to the activation of 5-HT2B receptors. This would aid in the 
development of a pharmacophore for agonism at 5-HT2B receptors. Identification of a 
pharmacophore will reveal which specific ligand structural features to avoid to prevent 5-HT2B 




















Figure 18. Correlation of DOX series compound binding data for compounds 21-40 (data taken 
from Table 3) between human 5-HT2A and 5-HT2B receptors. Slope = 0.937; r = 0.935; n = 16.111  
 
Clearly the study of the pharmacophoric requirements of 5-HT2A and 5-HT2B receptor 
activity, specifically 5-HT2A antagonism and 5-HT2B agonism, has important therapeutic 
implications in schizophrenia and proper cardiac function, respectively. The goal of this project is 
to evaluate specific compounds that target these receptors such as 5-HT2A antagonists, e.g., 
analogues of risperidone, and certain quipazine analogues (1-NP, isoquipazine), and 5-HT2B 





















The specific aims of this project are: 
1. Exploitation of a 5-HT2A receptor antagonist pharmacophore via affinity screening 
of compound 14 and elaboration of (i.e. adding specific substituents to) compound 





a. Synthesis of 14 and analysis of affinity screening data of 14 across multiple 
receptors 
b. Synthesis of an analogue of 14 to determine lipophilic/bulk tolerance in 5-HT2A 
receptors through propylation of the piperidine nitrogen 
c. Affinity studies of the analogue(s) synthesized in b. and elucidation of binding 
requirements at 5-HT2A receptors 
2. In silico 3D molecular modeling studies of plausible quipazine (45) binding modes 
at 5-HT2A receptors 
a. Docking studies of quipazine (45), isoquipazine (46), 2-NP (47), and 1-NP (48) at 
a crystal structure of the 5-HT2A receptor 
b. Hydropathic INTeraction (HINT) analysis of the identified poses in study 2a 
c. Comparison of the identified binding modes to crystal structures of known 5-HT2A 
ligand-protein complexes 
3. Development of a pharmacophore for 5-HT2B agonism 
a. Molecular modeling of nFen (20) and DOB (22) at 5-HT2A receptors to aid in 




b. Synthesis of new analogues of amphetamine (42) and DOB (22) on the basis 
of the above study 
c. Functional studies of the synthesized analogues utilizing a calcium (Ca2+) -
release assay to determine potencies 
d. Determination of agonist/antagonist properties of selected DOX 
phenylisopropylamine analogues in a Ca2+-release assay 
e. Formulation a pharmacophore for 5-HT2B agonism based on acquired 
functional data 








































IV. Approach, Results and Discussion 
 
A. Specific Aim 1: Exploitation of a 5-HT2A receptor antagonist pharmacophore via affinity 
screening of compound 14 and elaboration of (i.e. adding specific substituents to) 
compound 14 in an attempt to delineate the structural features necessary for conferring 5-
HT2A selectivity 
1. Approach 
In the deconstruction/elaboration analysis study of risperidone conducted by our 
group,76,77 it was revealed that a structure containing only the “left half” of risperidone does not 
bind to 5-HT2A receptors whereas structures containing only the “right half” of risperidone, as seen 
with abbreviated analogues 14 (Ki = 71.41 nM and IC50 = 20.12 μM) and 15 (Ki = 12.27 nM and 
IC50 = 7.40 μM), retain both nanomolar affinity and micromolar potency at 5-HT2A receptors, as 
compared to risperidone. This finding stresses the essential nature of the 6-fluoro-3-(4-
piperidinyl)-1,2-benz[d]isoxazole moiety for the binding of risperidone. Other important findings 
were that a tertiary amine is optimal for binding as secondary amine-containing analogues 
displayed significantly lower affinity than their tertiary amine counterparts, and a 6-fluoro 
substituent while beneficial, is not essential for binding at 5-HT2A receptors. These two findings 
are corroborated by similar results analyzing a series of truncated analogues of ketanserin.158 
In the same study, to determine the structural requirements of the “left half” of risperidone, 
UHS-308 (51; Figure 20) was synthesized. UHS-308 is a truncated analogue of risperidone 
containing only half of the “left half” (i.e. the 2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]-
pyrimidin-4-one) portion of risperidone. Specifically, the activity data of this compound at 5-HT2A 
receptors determined if the entire “left half” portion of risperidone is necessary. It was revealed 
that UHS-308 displays higher affinity (Ki = 1.9 nM) and potency (IC50 = 5.44 nM) than risperidone, 
suggesting that although activity is lost with a structure containing solely the “left half” portion, 
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some portion of the “left half” contributes to 5-HT2A receptor affinity and activity. Thus, these 




Figure 20.  Structure of UHS-308 (51). 
One avenue that was still yet to be explored regarded the bulk and lipophilic tolerance of 
the piperidinyl substituent. Thus far, it had been revealed that not all of the “left half” portion of 
risperidone is necessary (as in 51) for activity and that substituting the “left half” of risperidone 
with the “left half” of ketanserin produces a compound (18, Ki = 0.37 nM and IC50 = 0.7 μM) with 
the highest affinity and potency out of all the analogues analyzed, including risperidone. However, 
both compounds 18 and 51 contain lipophilic elements, electronegative atoms, and 6-membered 
rings within their piperidinyl substituents and so at this point it was still too early to determine bulk 
and lipophilic tolerance of the “left half” of risperidone. Compound 15 which contains a methyl 
substituent on the piperidinyl nitrogen showed improvement in both affinity and potency (Ki = 
12.27 nM; IC50 = 7.40 ± 1.45 μM) as compared to its des-methyl counterpart 14. This indicates 
that alkyl substituents are well tolerated at the piperidinyl nitrogen and thus poses a question: 
what is the effect of extending the alkyl chain at the piperidinyl nitrogen on affinity for 5-HT2A 
receptors? 
To answer this, in the current study a series of analogues of compound 14 with piperidinyl 
alkyl substituents of various lengths and sizes were designed (Figure 21). Extending the alkyl 
chain to ethyl (i.e., 52), propyl (i.e., 53), and butyl (i.e., 54) substituents would reveal what length 




substituent of analogue 55 is the same length as the butyl substituent of 54 but differs in bulk due 











Figure 21. Proposed analogues of compound 14. 
 
2. Results and Discussion 
a. Synthesis of 14 and analysis of affinity screening data across multiple receptors 
Before initiating the synthesis of compounds 52-55, compound 14 was synthesized in greater 
quantity for screening across various receptor types (5-HT2A-2C receptors, D1-5 dopamine 
receptors, and 1A,1B adrenergic receptors) along with its N-methyl counterpart 15, hybrid 
analogues 17 and 18, truncated analogue 51, risperidone (10), and ketanserin (16). The synthetic 













Scheme 1. Synthesis of compound 14 and 53.a 
 





aReagents and conditions: (i) Ac2O/HCOOH, 60 °C, 1 h; (ii) SOCl2/DMF, 3 h; (iii) 1,3-
difluorobenzene, AlCl3, reflux, 3 h; (iv) H2NOH·HCl/EtOH, NaOH/H2O, reflux, overnight; (v) 
NaH/DMF, 75 °C, 4 h; (vi) conc. HCl/EtOH, reflux, 3 h; (vii) 1-iodopropane, K2CO3, acetonitrile. 
 
Compound 14 was synthesized using a modified literature procedure.159 Intermediate 57 
was formed by protecting the amine of 56 using a formyl group donated by formic acid (HCOOH) 
to prevent the amine from forming bonds in subsequent reactions. This was a revised procedure 
as compared to that in the literature in that HCOOH and acetic anhydride (Ac2O) were used as 
separate reagents instead of using acetic-formic anhydride as in the literature. Compound 57 was 
then treated with thionyl chloride (SOCl2) to convert the carboxylic acid into an acid chloride. 















resulted in the acid chloride hydrolyzing back into the carboxylic acid. This was done by utilizing 
a guard tube filled with calcium chloride (CaCl2), flushing the reaction vessel with N2 gas before 
and during the reaction, and quickly opening and closing any rubber septa or stoppers during 
additions and transfers of materials. Compound 58 was then coupled with 1,3-difluorobenzene 
using a Friedel-Crafts reaction resulting in the ketone 59. Freshly sublimed aluminum chloride 
(AlCl3) was used for this reaction, as using un-sublimed AlCl3 resulted in multiple side products. 
Also, the reaction mixture was given enough time to cool to room temperature and was slowly 
added to water for quenching. Failure to do so resulted in the formation of a greyish, foam-like 
substance and decomposition of products. The carbonyl group of 59 was converted to an oxime 
using hydroxylamine hydrochloride (H2NOH·HCl) resulting in 60. The crude solid formed in this 
reaction was dissolved in water, the recrystallization solvent; however, solid remained regardless 
of how much water was added. After removing the water under reduced pressure and redissolving 
the remaining solid, again solid remained. Melting point analysis indicated that this solid is a salt 
formed in the reaction, most likely NaCl, due to its very high melting point (>400 °C). Eventually, 
enough water was added to dissolve most of the crude solid and the remaining solid was removed 
using a spatula. Recrystallization using this method was successful and resulted in the formation 
of a solid in the form of small white crystals. This reaction did not produce a specific isomeric 
product so both the E and Z isomers of the oxime are formed, producing two stacked spots on 
TLC. However, during the ring closure reaction forming the benzisoxazole ring in 61, only the Z 
isomer reacts, corresponding to one of the spots disappearing and the formation of a new spot 
(representing 61). The sodium hydride that was used for this reaction was dispersed 60% in 
mineral oil and so was washed in toluene prior to mixing with the other reagents. Finally, the 
formyl protecting group attached to the piperidine nitrogen in the first reaction was hydrolyzed and 




The affinity data from the radioligand binding screen revealed information regarding the 
selectivity of compounds 14, 15, 17, 18, 51, risperidone (10), and ketanserin (16) for 5-HT2A 
receptors. The acquired data are shown in Table 5. The affinity data acquired for the compounds 
from the UNC-Chapel Hill Psychoactive Drug Screening Program at 5-HT2A receptors 
corroborates the 5-HT2A receptor radioligand binding results that we recently published.77 
Synthesized compound 14 displays nanomolar affinity (Ki = 39.1 nM) at 5-HT2A receptors as 
expected. However, one new finding from this screen is that it also displays selectivity for 5-HT2A 
receptors over the other receptor types analyzed. Closer analysis of the data reveals certain 
trends in affinity. For example, increasing the length and bulk of the piperidinyl substituent of 
compound 14, as seen with compounds 15, 51, and 18, results in greater 5-HT2A receptor affinity 
(Ki = 10.6, 3.0, 0.62 nM, respectively) and greater selectivity for 5-HT2A receptors over the 
“undesirable” receptors (5-HT2B, D1-4, and 1A,1B adrenergic receptors). However, this same 
increase in the piperidinyl substituent size is correlated with an increase in D2 receptor affinity (Ki 
= 1081, 374, 154 nM, respectively). Decreasing bulk of the piperidinyl nitrogen results in lower 










Table 5. Radioligand binding screen of compounds risperidone (10), 14, 15, ketanserin (16), 17, 

















































































































































































































































































































































b. Synthesis of an analogue of 14 to determine lipophilic/bulk tolerance in 5-HT2A receptors 
through propylation of the piperidine nitrogen 
Initially, we proposed to prepare and examine four N-substituted analogues of 14, shown 
in Figure 21. As mentioned previously, antipsychotic-induced extrapyramidal stimulation is 
primarily precipitated by D2 receptor antagonism. Therefore, one of the primary objectives of this 
study was to elaborate on the pharmacophoric requirements of 5-HT2A antagonists necessary for 
achieving greater selectivity for 5-HT2A receptors versus D2 receptors, as well as low affinity for 
D2 receptors. The results in Table 5 reveal that extension of the chain on the piperidinyl nitrogen 
results in greater affinity and selectivity for 5-HT2A receptors, but also higher affinity for D2 
receptors. Furthermore, the N-propyl compound 53 has been reported to possess high affinity for 
D2 receptors (Ki = 34 nM),160 suggesting that extending the chain beyond the length of a propyl 
substituent might confer greater D2 affinity – thus calling into question our original plan to probe 
the binding site of 5-HT2A receptors by gradually extending the alkyl chain on the piperidinyl 
nitrogen. Therefore, it was our decision to change directions and forgo the synthesis of the N-
ethyl (i.e., 52), N-butyl (i.e., 54), and N-benzyl (i.e. 55) analogues.  
Although the D2 receptor affinity of 53 has been reported, its 5-HT2A receptor affinity has 
not. The propyl chain of 53 might represent an intermediate substituent length (i.e. a “Goldilocks” 
length) in relation to the other analogues in Figure 21 and so its affinity at 5-HT2A receptors might 
best elaborate the lipophilic and bulk requirements of the piperidinyl substituent. Hence, 53 was 
chosen to be synthesized and analyzed for 5-HT2A receptor affinity in a radioligand binding assay 
using HEK293 cells stably expressing human 5-HT2A receptors and [3H]-ketanserin as the 
radioligand. 
Compound 53 was synthesized using a standard alkylation reaction that proceeds through 
an SN2 reaction mechanism as represented in Scheme 1. The nucleophilic nitrogen atom of the 
piperidine ring of 14 contains a lone pair of electrons which form a bond to the  carbon atom of 
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1-iodopropane, displacing the iodide atom. The purpose of the weak base K2CO3 is to trap the HI 
formed. Salt formation of the free base form of 53 was originally attempted by the dropwise 
addition of concentrated HCl in methanol (MeOH) directly onto the crude free base oil. However, 
this resulted in a black solution and TLC of the solution indicated that the free base had 
decomposed, resulting in numerous spots. This suggested that directly adding HCl/MeOH onto 
the free base is too harsh and exothermic, causing the breaking of bonds and fragment formation. 
Compound 53 was eventually successfully formed by dissolving its free base form in Et2O and 
adding HCl/Et2O in a dropwise manner into the solution, resulting in the formation of a white 
precipitate. This precipitate was initially purified using only MeOH as the recrystallization solvent, 
however, this resulted in a low yield of crystals. Using a two-solvent system of MeOH and Et2O 
resulted in a much higher yield of precipitated crystals because of the nonpolar environment in 
the solution. 
c. Affinity data for 53 and discussion of results 
Compound 53 displayed a pKi value of 6.97 ± 0.23 (or a Ki value of 107.3 nM) in our binding assay 





































The affinity value for 53 (107.3 nM) was unexpected considering the trend of greater piperidinyl 
substituent length/bulk accompanied by greater affinity for 5-HT2A receptors, as seen in Table 5. 
Adding a methyl substituent onto the piperidine nitrogen atom of 14 resulted in an increase in 
affinity from 71.4 nM to 12.3 nM for 15. The next compound in Table 5, 51, a compound that 
introduces a bulky aromatic ring in addition to greater piperidinyl substituent length, produced an 
affinity of 1.9 nM. Following this trend, one would expect a compound containing a piperidinyl 
substituent of intermediate length (i.e. 53) to display an affinity higher than that of 15 but less than 
that of 51 (i.e. less than 12.3 but greater than 1.9 nM). Instead, we observed a jump to 107.3 nM 
upon increasing the chain length to a propyl chain as in 53. This might be explained by there 
being a tolerance for length of simple alkyl chains on the piperidinyl nitrogen. Perhaps, only alkyl 
chain substituents shorter than propyl chains are well tolerated and any longer substituent 
requires an associated aromatic ring and/or heteroatoms as in 51. This would be explained by 
phenylalanine or tyrosine residues forming - interactions with aromatic moieties in the molecule 
or hydrogen bonding between polar amino acids such as serine or threonine and heteroatoms. 
An alkyl chain substituent as long as a propyl chain might not make adequate interactions with 
these amino acids or may result in a steric clash with amino acids. To test this theory, the other 
compounds in Figure 21 (52, 54, and 55) can be synthesized and tested for their affinity for 5-
HT2A receptors. Affinity data of these compounds will reveal the limit of bulk tolerance of the region 
of the binding site occupied by alkyl chain substituents. With our affinity data for 53, the most we 
can conclude is that a propyl chain is not well tolerated. However, the ethyl group may follow the 
trend in affinity mentioned above. Assuming that a three-carbon chain is the longest alkyl chain 
tolerated at the piperidine nitrogen atom, the N-butyl compound 54 should possess lower affinity 
than 53. If an aromatic moiety contained within the substituent increases affinity via participation 
in - aromatic interactions, the N-benzyl compound 55 should have higher affinity as compared 
to 53 and 54. 
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B. Specific Aim 2: In silico 3D molecular modeling studies of plausible quipazine (45) 
binding modes at 5-HT2A receptors 
1. Approach 
Elucidation of the binding mode of quipazine (45) at 5-HT2A receptors would be an 
important step toward the determination of its possible hallucinogenic activity. Due to quipazine’s 
unique structural scaffold (as compared to other classical hallucinogens), its binding mode may 
represent a new way of eliciting hallucinogenic activity, via interactions with specific amino acids 
in the binding site of 5-HT2A receptors that were never considered before. Hence, computational 
docking and analysis of quipazine could provide essential information. Aiding this effort, the bound 
crystal structures of hallucinogens 25CN-NBOH (PDB ID: 6WHA) and LSD (PDB ID: 6WGT) have 
been published. This allows for comparison of docked poses of quipazine to those of known 
hallucinogens and 5-HT2A agonists, providing more evidence for, or lack thereof, of quipazine’s 
unique manner of binding. 
In this study quipazine and its isostere 2-NP (47), as well as its positional isomers 
isoquipazine (46) and 1-NP (48) were docked into the crystal structures of 5-HT2A receptors. To 
corroborate our computational results, we obtained affinity and functional activity data for all four 
compounds (Table 6), from Dr. Maeso’s laboratory.125 The differences in the activity of these 
compounds are quite revealing. For example, comparison of the activities of quipazine and 2-NP, 
as well as isoquipazine and 1-NP reveals that the aromatic nitrogen atoms detract from both 
affinity and functional activity. Furthermore, translocating the piperazine substituent from the 2-
position to the 1-position of the aromatic ring results in antagonism as seen with isoquipazine and 
1-NP. Computational analyses including HINT analyses of these compounds might assist in 




Table 6. Affinity, calcium mobilization, drug discrimination (DD), and heat twitch response (HTR) 













1995 EC50 = 7261 1.7 ED50 = 3.4 
2-NP 
(47) 
724 EC50 = 150 2.9 ED50 = 0.2 
Isoquipazine 
(46) 









To gain insight on how quipazine and its analogs might bind at 5-HT2A receptors, we 
generated two models of the h5-HT2A receptor-based X-ray crystal structures of the active state 
(PDB ID: 6WHA) and the inactive state (PDB ID: 6A94). Docking studies using the models and 
quipazine analogs were conducted to identify potential binding modes of the agonists and 
antagonists. Agonists, quipazine (45) and 2-NP (47), were docked to the active state model and 
antagonists, isoquipazine (46) and 1-NP (48), were docked to the inactive state model. A built-in 
clustering program was used to cluster the docked solutions with an RMSD cutoff of 0.75 Å. Both 
solutions in the most populated cluster and solutions in the highest scoring cluster were analyzed. 
Individual interactions were then analyzed using Hydropathic INTeractions (HINT) analysis.161 
HINT classifies and scores hydrophobic and polar interactions, collectively known as hydropathy, 
for each atom; the higher the score, the more favorable the interaction. The software utilizes 
experimental data from solvent partitioning experiments between water and 1-octanol (LogPo/w) 
to determine HINT scores of interactions by assigning positive scores for favorable interactions 
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(hydrogen bonding, acid-base, and hydrophobic) and negative scores for unfavorable interactions 
(acid-acid, base-base, hydrophobic/polar).161 
 
2. Results and Discussion 
Docked solutions revealed two possible binding pockets occupied by the aromatic 
moieties of the compounds. Regardless of which binding pocket is utilized, all ligand-protein 
complexes formed a salt bridge between the N4’ atom and conserved Asp1553.32 within hydrogen 
bond (HB) distance (3.5 Å). The observed ionic, hydrophobic and polar interactions between 
ligands and protein are supported by HINT analysis (Table 7). 
Table 7. GOLD and HINT interaction scores (total, hydrogen bonding, hydrophobic, acid/base) of 
quipazine (45), 2-NP (47), isoquipazine (46) and 1-NP (48) at 5-HT2A receptors. 
 
Score Quipazine 2-NP Isoquipazine 1-NP 
GOLD 41 41 44 45 
Total HINT 899 1496 1121 1454 
Total H-Bond 818 1082 916 1009 
Total Hydrophobic 239 501 479 649 
Total Acid/Base 409 362 476 439 
 
Examination of the various clusters as well as the HINT analysis of the compounds 
revealed their likely binding poses. Gold docking of quipazine and 2-NP at the active state 
receptor model revealed two primary clusters – one containing the highest scoring pose (in the 
binding pocket designated as the large principal pocket) and another containing the greatest 
population of solutions (in the binding pocket designated as the small sub-pocket). An analysis of 
the top scoring solution from each cluster is shown in Figure 23. Our selection of their probable 




revealed that the selected pose for 2-NP has a much higher total interaction score (1496) than 
quipazine (899). Furthermore, 2-NP has a significant hydrogen bond between the backbone 
oxygen atom of Ile1523.29 and N4, an interaction that is lacking in the quipazine docked solution. 
Quipazine has a moderate hydrogen bond score between Ser1593.36 and N1. Due to quipazine’s 
possible proclivity for forming this reaction, it might forgo the numerous hydrophobic interactions 
as seen with 2-NP (forcing it to occupy a different binding site), supported by their total 
hydrophobic scores: 239 for quipazine and 501 for 2-NP. All these results are in accordance with 










Figure 23. Top GOLD scoring solutions of quipazine (45) (capped sticks rendering; green carbon 
atoms), 2-NP (47) (capped sticks rendering; magenta carbon atoms), isoquipazine (46) (cyan 
carbon atoms), and 1-NP (48) (capped sticks rendering; yellow carbon atoms) in the binding site 
of their respective [i.e., active (PDB ID: 6WHA) or inactive (PDB ID: 6A94) state] 5-HT2A receptor. 
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Gold docking of 1-NP and isoquipazine revealed two primary clusters – one containing the 
highest scoring pose (in the binding pocket designated as the large principal pocket) and another 
containing the greatest population of solutions (in the binding pocket designated as the small sub-
pocket) (Figure 24). HINT analysis resulted in a higher total interaction score for the chosen pose 
of 1-NP (1454) than for the chosen pose of isoquipazine (1121). Inspection of individual 
interactions revealed an acid/base interaction between N2 in isoquipazine and Asn3436.55. This 
possible interaction might be the reason for isoqupazine occupying a different binding site 
compared to 1-NP. As a result, isoquipazine does not have as many hydrophobic interactions as 
1-NP, supported by their total hydrophobic scores: 479 for isoquipazine and 649 for 1-NP. These 
results are in accordance with the higher affinity of 1-NP as compared to that of isoquipazine. 
Analysis of the chosen complexes (Figure 24) revealed that the two compounds with the 
highest affinity (1-NP and 2-NP) faced the same binding pocket and participated in similar 
hydrophobic interactions – numerous interactions with Leu228ECL2 and Leu3627.35. 1-NP 
additionally displayed hydrophobic interactions with Val2355.39 and Val3667.39. Quipazine and 
isoquipazine faced a different binding pocket, although the two molecules did not overlap. As a 
result, quipazine primarily displayed hydrophobic interactions with Gly3697.42 and Val3667.39 and 




















Figure 24. Binding modes of quipazine (45) (capped sticks rendering; cyan carbon atoms), 2-NP 
(47) (capped sticks rendering; magenta carbon atoms), isoquipazine (46) (white carbon atoms), 
and 1-NP (48) (capped sticks rendering; blue carbon atoms) in the binding site of the 5-HT2A 
receptor using both the active (6WHA) and inactive (6A94) states of the receptor. 
 
It appears that hydrophobic interactions predominate for the examined analogues to elicit 
binding at 5-HT2A. This assertion is based on the simplicity (lack of substituents/hydrophobic 
nature) of the compounds along with the numerous hydrophobic interactions revealed by HINT 
analysis. Because 1-NP and 2-NP face a similar binding pocket, it can be suggested that 
compounds interacting with residues in this pocket possess the highest affinity. Furthermore 













is shown to be in an edge-to-face position (4.0 - 4.6 Å) relative to the aromatic moieties of 1-NP 
and 2-NP (not shown by HINT analysis). Quipazine and isoquipazine, however, face away from 
this pocket and this might be the reason for their low affinity. These two compounds also have 
aromatic nitrogen atoms in their structures (which 1-NP and 2-NP lack); this suggests that 
heteroatoms within the aromatic ring structure of these analogues decrease their affinity and the 
greater the hydrophobic nature of the aromatic ring, the greater the affinity. 
Our modeling results also revealed similarities in the binding of agonists quipazine and 2-
NP and agonists/hallucinogens LSD and 25CN-NBOH. Similarities were also observed in the 
binding of antagonists isoquipazine and 1-NP and antagonist risperidone (Figure 25). The bound 
crystal structures of LSD (PDB ID: 6WGT), 25CN-NBOH (PDB ID: 6WHA), and risperidone (PDB 
ID: 6A93) have been published.  The comparison of the binding modes of these ligands with the 
binding modes of quipazine and its analogues revealed that certain features of LSD, 25CN-
NBOH, and risperidone might be essential for their binding and activity at 5-HT2A receptors.  
Quipazine utilized amino acids common to the binding of 25CN-NBOH. Specifically the oxygen 
atom of the 2-hydroxy benzyl moiety of 25CN-NBOH and the nitrogen atom of the quinoline ring 
of quipazine participated in hydrogen bonding with Ser1593.36. The two moieties also shared 
significant overlap in the binding pocket. Comparison of the binding of LSD and 2-NP revealed 
that the diethyl amide moiety of LSD and the naphthalene moiety of 2-NP occupy a similar region 
of the binding pocket indicating that they might participate in similar hydrophobic interactions. The 
antagonists isoquipazine and 1-NP share space with key features of the antagonist risperidone. 
For example, the naphthalene moiety of 1-NP shares a binding pocket occupied by the 
pyrimidinone moiety of risperidone. Isoquipazine on the other hand shares a distinct binding 
pocket occupied by the benzisoxazole moiety of risperidone. This observation is in accordance to 
findings previously published by our group76,77 indicating that the entire structure of risperidone is 











Figure 25. Comparison of binding poses of (A) quipazine (45) (capped sticks rendering; cyan 
carbon atoms) and 2-NP (47) (capped sticks rendering magenta carbon atoms) with 25CN-NBOH 
(capped sticks rendering; green carbon atoms), (B) quipazine and 2-NP with LSD (capped sticks 
rendering; yellow carbon atoms), and (C) isoquipazine (46) (capped sticks rendering; white 
carbon atoms), and 1-NP (48) (capped sticks rendering; blue carbon atoms) with risperidone 
(capped sticks rendering; dark pink carbon atoms) in the binding site of the 5-HT2AR using both 
the active (6WHA) and inactive (6A94) states of the receptor. Hydrogen bonds are indicated by 









C. Specific Aim 3: Development of a pharmacophore for 5-HT2B agonism 
1. Approach 
As mentioned previously, there is value in elucidating the structure-activity relationship of 
phenylisopropylamines at 5-HT2B receptors in relation to prevention of cardiac valvulopathy as 
well as to breaking ground in pharmacophoric evaluation of 5-HT2B receptors. To this aim, 
molecular docking and Hydropathic INTeraction (HINT) score analysis of two representative 
phenylisopropylamines DOB (22) and nFen (20) were performed. DOB possesses high affinity for 
5-HT2B receptors (Ki = 26.9 nM) and even higher affinity for 5-HT2A receptors (Ki = 0.6 nM).111 
DOB exhibits agonist action at 5-HT2B receptors (EC50 = 2.88 nM) along with its iodo-substituted 
counterpart, DOI (EC50 = 1.41 nM).121 Both compounds, DOB and nFen, share similar structural 
scaffolds – both contain the structure of amphetamine (42) in their structures. This is a peculiar 
insight because both DOB and nFen have been shown to display affinity for and activity at 5-HT2B 
receptors; however, there is no evidence for amphetamine displaying any such activity. 
Furthermore, there has been no evidence for amphetamine resulting in cardiac valvulopathy in 
patients despite being used clinically for decades, indicating amphetamine’s inability to activate 
5-HT2B receptors. This leads to the conclusion that the 3-position CF3 substituent of nFen must 
be responsible for nFen’s affinity for 5-HT2B receptors. Thus, the interactions of the 3-CF3 
substituent with specific amino acids in the binding pocket of 5-HT2B receptors represent crucial 
points of interest in regard to eliciting affinity and activity at these receptors. Similar insights can 
be claimed when considering DOB: DOB’s affinity for 5-HT2B receptors must be dependent on the 
interactions of one or more substituents of its phenyl ring (2-OCH3, 4-Br, 5-OCH3) with key amino 
acids in the binding pocket. Because crystal structures of 5-HT2B receptors had been published,146 
it was decided that computational analysis of these compounds would be the best method to 




2. Results and Discussion 
a. Molecular docking of R(-)-DOB and S(+)-nFen using the crystal structure of the 5-HT2B 
receptor 
The 5-HT2B crystal structure (PDB ID: 6DRY) was used due to its relatively high resolution (2.9 Å) 
and it being crystallized with the known 5-HT2B agonist methylergonovine, thus representing an 
active state of the 5-HT2B receptor appropriate for the docking of the representative agonists DOB 
(22) and nFen (20). Specifically R(-)-DOB, S(+)-DOB, and S(+)-nFen were analyzed using this 
crystal structure. Both isomers of DOB were analyzed because there is a lack of data 
distinguishing the activity of individual isomers of DOB at 5-HT2B serotonin receptors. However, it 
should be noted that R(-)-DOI (Ki = 9.9 nM) binds with higher affinity than S(+)-DOI (Ki = 35 nM) 
at 5-HT2A receptors;119 hence, there is evidence for differences in the activity of individual isomers 
of phenylisopropylamines at serotonin receptors. S(+)-nFen was chosen due to its higher 5-HT2B 
receptor affinity (Ki = 11.2 nM) and greater functional activity in phosphoinositide hydrolysis (Kact 
= 18.4 nmol/L) than its enantiomer R(-)-nFen (Ki = 47.8 nM and Kact = 357 nmol/L) and was thus 
deemed a better indicator for agonism at 5-HT2B receptors than R(-)-nFen. 
All three structures, R(-)-DOB, S(+)-DOB, and S(+)-nFen, were drawn using SYBYL-X 
2.1.1 and were energy minimized utilizing the Tripos Force Field with Gasteiger-Hückel charges, 
a non-bonded interaction cutoff of 8 Å, dielectric constant (ε) of 4.00 D/Å, and a termination 
gradient of 0.05 kcal/(mol*Å). The structures were then docked at the 5-HT2B receptor crystal 
structure using GOLD v5.6 which generated 100 protein-ligand complexes for each compound 
and GOLD scores, based on an in-program scoring system, for each complex. Each complex was 




All of the complexes with S(+)-DOB docked at the 5-HT2B receptor resulted in much lower 
GOLD and HINT scores than the complexes with R(-)-DOB. As a result, S(+)-DOB was eliminated 
from further consideration and focus was on R(-)-DOB. The most significant observation from the 
docking results was that the phenyl rings of R(-)-DOB and nFen were shifted relative to each other 
but they participated in similar interactions in the binding site (Figure 26). Both formed salt bridge 
interactions with the conserved Asp1353.32 residue. R(-)-DOB participated in hydrogen bonding 
with Asn3446.55 via the 5-OCH3 group oxygen atom and the 4-Br substituent; additionally, the 4-
Br substituent participated in hydrogen bonding with Ser2225.43. One of the fluoro (F) atoms of 
nFen participated in bifurcated hydrogen bonds with Asn3446.55 and Ser2225.43; another F atom 
was involved in a single hydrogen bond with Asn3446.55. These results indicate that both R(-)-
DOB and nFen participate in the same specific hydrogen bonding interactions (with Asp1353.32, 
Asn3446.55, and Ser2225.43). HINT analysis agreed with the observed interactions of R(-)-DOB and 
nFen (Table 8 and Table 9). The R(-)-DOB 4-Br substituent interactions with Asn3446.55 and 
Ser2225.43, and the hydrogen bond of the oxygen atom of the 5-OCH3 substituent with Asn3446.55, 
produced favorable HINT scores. One of the F atoms of the CF3 substituent of nFen hydrogen 
bonded with Asn3446.55 and Ser2225.43 with positive HINT scores whereas another F atom formed 
favorable hydrogen bonds with Asn3446.55 with a positive HINT score. The nitrogen atoms of R(-
)-DOB and nFen formed bidentate hydrogen bonding interactions with the Asp1353.32 residue with 
















Figure 26. Docked poses of R(-)-DOB (capped sticks rendering; cyan carbon atoms) and nFen 
(capped sticks rendering; magenta carbon atoms) in the binding site of the 5-HT2B receptor. 




      *500 units = 1 kcal/mol 







Hydrogen Bond HINT 
Score* 
4-Br to Asn344 108 
4-Br to Ser222 34 
5-O to Asn344 39 
N to Asp135 1637, 1580 
nFen 
Interactions 
Hydrogen Bond HINT 
Score 
F to Asn344 36 
F to Ser222 14 
F’ to Asn344 34 









Because of the structural similarity between R(-)-DOB and nFen, it was expected that the 
phenyl moieties would be strictly superimposed in the binding site. Instead, my modeling studies 
showed that the phenyl moieties were skewed relative to one another, with the 4-Br substituent 
of R(-)-DOB and the 3-CF3 group of nFen being located in the same position (Figure 26). The 4-
Br atom of R(-)-DOB and 3-CF3 of nFen both utilized Asn344 and Ser222 for hydrogen bonding 
interactions, supporting the hypothesis that these interactions are crucial for the binding of 
phenylisopropylamines. However, because only two F atoms of nFen participated in hydrogen 
bonds with the receptor, the third F might not be required for activity. Furthermore, although 
required for 5-HT2A binding,119 the oxygen atom of the 2-OCH3 group of R(-)-DOB might not be 
necessary for binding at the 5-HT2B receptor as shown by the lack of strong interactions (i.e. 
hydrogen bonding), supported by the HINT analysis. These results allowed us to propose the first 
working pharmacophore for 5-HT2B ligands (Figure 27) which consists of an amine (N) separated 
by 5.2 Å from an aryl ring containing electrostatic (or possibly hydrophobic) substituents at either 
the 3- and/or 4-positions.  Based on this putative pharmacophore, new analogs were designed to 


























There are two primary questions that need to be addressed through the functional activity 
analysis of the designed compounds. The first question is this: is the binding of nFen at 5-HT2B 
receptors dependent on the lipophilic or electronic character of the phenyl substituent? As 
surmised above, the 3-CF3 substituent of nFen is required for binding at 5-HT2B receptors. 
However, the CF3 substituent forms both lipophilic and electronic interactions with the binding site 
( = 0.88, σ = 0.43).164 Therefore, compounds would need to be designed whose functional data 
will help elucidate this binding requirement. One of these compounds that was proposed was 
compound 65 (Scheme 2). Replacing the 3-CF3 with 3-CH3 as in 65 will allow us to determine if 
lipophilic character of the phenyl substituent is most essential for the binding of nFen (20) because 
the CH3 substituent ( = 0.56, σ = -0.07) has similar lipophilic character but opposite electronic 
character as compared with CF3. If 65 is equipotent to nFen then it can be concluded that lipophilic 
character predominates for the binding of nFen at 5-HT2B receptors; if 65 is less potent than nFen, 
then electronic character predominates. Another proposed compound was compound 68, a 
positional isomer of 65, which contains a CH3 substituent in the 4-position as opposed to the 3-
position as in 65. If lipophilic character of the phenyl substituent is determined to be most essential 
for the binding of nFen, then 68 should display similar activity as 65. This might be possible 
through a relative shift of the phenyl rings of 68 as compared with 65 in the binding site (as 
proposed in Figure 26) to allow their phenyl substituents to participate in the appropriate 
interactions with residues to elicit activity at 5-HT2B receptors. 
The second question that must be addressed is: is the 2-position OCH3 substituent of DOB 
necessary for 5-HT2B receptor activity? Preliminary modeling studies indicated that there are no 
substantial interactions such as hydrogen bonding between the 2-OCH3 of DOB and the binding 
site residues. To assess the necessity of this substituent the des-2-methoxy-DOB compound 71 
will be prepared. If 71 produces similar activity as DOB in functional studies, we can conclude 
that the 2-OCH3 is not required for activity. However, if activity decreases with removal of the 2-
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OCH3 substituent, then it is required and participates in electronic and/or hydrophobic interactions 
with the binding site of 5-HT2B receptors. 
Functional activity analysis of all three designed compounds as well as a series of DOX 
phenylisopropylamine compounds [DOF (21), DOB (22), DOI (23), MEM (28), DON (30), DOPR 
(32), DOHx (33), DOTB (34), and DOBz (35)] will be conducted to obtain EC50 values. This 
information will allow us to elaborate on the SAR of phenylisopropylamines and furthermore on 
the pharmacophoric requirements to activate 5-HT2B receptors. 
 
b. Synthesis of compound 65, 68, 71 
The syntheses of 65 and 68 are illustrated in Scheme 2. The nitrostyrene intermediate 64 
was synthesized using a Henry reaction during which a base-catalyzed addition of nitroethane 
occurs followed by expulsion of water and formation of a double bond. The resulting product was 
successfully purified using a CombiFlash purification method and bright yellow needle-like 
crystals precipitated upon addition of EtOH and cooling. The nitrostyrene intermediate 67 was 
also synthesized using the Henry reaction; however, the purified product remained an oil rather 























aReagents and conditions: (i) NH4OAc/Nitroethane, reflux, 48 h; (ii) LiAlH4/THF, reflux, 2 h; (iii) 
NH4OAc/Nitroethane, reflux, overnight; (iv) LiAlH4/THF, reflux, 2 h; (v) NH4OAc/Nitroethane, 
reflux, overnight; (vi) NaBH4/THF, boron trifluoride diethyl etherate, 5.5 h. 
 
The final amines 65 and 68 were synthesized from their respective nitrostyrene 
intermediates via a LiAlH4 reduction reaction. The reduction was initially attempted with 64 before 
proceeding to and applying the same method to the synthesis of 68. I initially attempted to purify 




















TLC analysis of the collected fractions revealed that numerous products distilled together, thus 
not allowing purification. Next, an attempt was made to purify the crude oil product of 65 by 
precipitating the HCl salt of the final amine via addition of ethereal HCl into a solution of the crude 
oil dissolved in Et2O. However, this resulted in the solution slowly turning black; a TLC analysis 
of this black solution revealed numerous spots, suggesting decomposition of the product. Clearly, 
precipitating a pure salt from a crude oil is not possible using this method and a purer oil is possibly 
needed to prevent decomposition. Another issue with this reaction was that I was likely not using 
enough LiAlH4 in the reductions. Equivalences of 1:1.77 and 1:4 of the nitrostyrene:LiAlH4 proved 
unsuccessful in completely consuming the nitrostyrene during the reaction. Finally an equivalence 
of 1:7 was used that successfully consumed the starting material, indicating the need of a large 
excess of reducing agent in the reduction of these nitrostyrenes. Using this equivalence and a 
purification method using the CombiFlash proved successful in producing the final amine as a 
pure free base in oil form which was successfully converted into an HCl salt via addition of ethereal 
HCl to a solution of the pure free base dissolved in Et2O. 
The synthesis of 71 is also displayed in Scheme 2. The Henry reaction was also used in 
the synthesis of the nitrostyrene intermediate. Based on prior knowledge of the possibility of the 
removal of bromo substituents from phenyl rings through the use of strong reducing agents such 
as LiAlH4. The reduction was attempted using mild reducing agent NaBH4/BF3. After performing 
an acid base extraction to purify the resulting crude product, ethereal HCl was added in a dropwise 







c. Functional activity studies of 65, 68, 71, and a series of DOX compounds 
 Functional analysis of the selected compounds mentioned above was initially attempted 
using the Flexstation 3 Multimode Microplate Reader, which is an automated instrument designed 
to acquire functional data of compounds in a high-throughput manner. This method utilized 
HEK293 cells transiently transfected with a 5-HT2B plasmid using the transfection agent 
Lipofectamine Reagent and the fluorescent dye Fura-2 to measure the calcium signal. However, 
this method ultimately proved unsuccessful. Despite spending months developing proper 
technique in areas such as cell culturing, pipetting/aspirating, making solutions, and general 
laboratory procedure, as well as optimizing numerous experimental variables such as cell density, 
amount of Lipofectamine Reagent, and amount of 5-HT2B plasmid used, the cells would not 
produce appreciable signals and required massive concentrations of the test compound 5-HT to 
elicit any effect. A representative concentration response curve is displayed in Figure 28 showing 
the inaccuracy of the data acquired using the Flexstation 3. The pEC50 of 5-HT from this curve is 







Figure 28. Representative concentration-response curve of 5-HT at 5-HT2B receptors using the 
Flexstation 3 Multimode Microplate Reader with transiently transfected HEK293 cells. pEC50 = 
3.36. 








































 Because collection of proper signals from the Flexstation 3 was unsuccessful, the 
fluorescent microscope was employed in hopes of achieving greater sensitivity. The fluorescent 
microscope (Figure 29) that was used is connected to a constant perfusion system by which 
imaging solution and solutions of the drug of interest are constantly perfused through the wells 
while simultaneously being evacuated through a vacuum hose. This enables constant exposure 
of the cells to the drug during the drug phases of a trial and quick and thorough washing of the 
cells with imaging solution during the washing phases. This is in contrast to the Flexstation 3 
which only has one addition of the drug solution to the wells containing the cells in imaging 
solution, thereby requiring the drug solution to diffuse through the imaging solution down to the 
cells at which point the cells very slowly react to the drug which might prevent the full potential of 
the signal caused by the drug from being reached. The fluorescent microscope methodology also 
includes individual selection of cells for the recording of data. The microscopy analysis system 
Live Acquisition is used during the trials to produce a video of the cells within the selected region 
of the wells. During activation of the receptors upon addition of an agonist, the cells display 
fluorescence, corresponding to the cells becoming brighter (whiter) in the video. The image 
processing software Fiji is then used to select individual cells that are representatives of this 
change in brightness. This difference is then averaged across all the selected cells from different 
wells and the average value represents the degree of activation of the cells. This is a much more 
sensitive method of recording signal as compared to the Flexstation 3. In the Flexstation 3 the 
overall fluorescence from the entire well is recorded by the instrument upon addition of a drug. 
This fluorescence is then subtracted by the baseline fluorescence, which is again a recording of 
the fluorescence from the entire well (but before any additions). This baseline fluorescence is 
quite high already due to the steady level of fluorescence constantly produced by the cells 
themselves. This would cause the signal from the addition of the drug to be extremely diminished. 
When processing data from the fluorescent microscope, the baseline fluorescence is collected for 
each individual cell, thus ensuring that any fluorescent signal from a drug is fully recognized for 
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that cell. In addition all fluorescent signals collected are subtracted by the background of the well 











Figure 29.  Photo of the fluorescent microscope used to acquire functional data of compounds at 
5-HT2B receptors. 
 
 When initially using the fluorescent microscope, the transfection agent Fugene and the 
calcium indicator GCaMP were employed. GCaMP is a fluorescent protein that is a chimera of 
green fluorescent protein, calmodulin (calcium binding protein), and the calmodulin interacting 
peptide M13.165 During the transfection phase of the experimental preparation, both the 5-HT2B 
plasmid and the GCaMP plasmid are transiently transfected into the HEK293 T cells using 
Fugene. When the cells divide and multiply, they will express the plasmids for a temporary amount 
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of time (i.e. transient transfection). When cells intracellularly release calcium upon agonist binding 
to 5-HT2B receptors, calcium binds to GCaMP thus producing measurable fluorescence. 
 Using the fluorescent microscope, greater sensitivity in the signal from the cells was 
achieved. I was able to produce signal at much lower concentrations of 5-HT than used previously 
with the Flexstation 3 (Figure 30). Although the data acquired from the fluorescent microscope 
was a much better representation of the actual functional data of the compounds tested, there 
were still some issues which needed to be addressed. Out of all cells cultured in the 96-well plates 
used for experiment, only a small percentage (~30%) of cells appeared to be transfected – i.e. 
few cells fluoresced at 490 nm of light when viewed under the microscope. The pEC50 value of 5-
HT (pEC50 = 7.44) was still not as high as that reported in the literature (pEC50 = 8.68)121 where 
Porter et al.121 also employed a calcium-flux assay, albeit with CHO-K1 cells stably transfected 
with 5-HT2B receptors. Another significant issue was regarding the variability in the signal being 
produced, represented both by the large standard error values/standard error of mean bars in the 
concentration-response curves as well as in the videos of the cells producing signal on the day of 
the experiment. The videos revealed that, although there were cells which were transfected (i.e., 
accepted and expressed the GCamP plasmid), not all of the transfected cells produced signal. 
Furthermore, amongst the cells producing signal, there were inconsistencies in the degree of 
signal being produced; some cells released more calcium than others and in turn fluoresced much 
more brightly than other cells. This would indeed result in large variability in the concentration-














Figure 30. Normalized (to 1 μM 5-HT) concentration-response curve of 5-HT at 5-HT2B receptors 
using the fluorescent microscope and transiently transfected HEK293 cells. pEC50 = 7.44 ± 0.22 
(EC50 = ~36.73 nM). 
 
Due to the inadequacies in transient transfection of the cells using the 5-HT2B plasmid 
available, we surmised that the cells either did not harbor the plasmid within their DNA for very 
long or did not accept the 5-HT2B plasmid to any great degree to begin with. The 5-HT2B plasmid 
that was used contained a 3x-hemagglutinin (HA) tag sequence at the N-terminus of the main 
sequence. These HA-tags are generally added to proteins to allow for simple means of purification 
such as metal-affinity chromatography using a Ni2+ column. However, we hypothesized that this 
HA-tag might be interfering with some step in the transfection process, either in the transfection 
itself or in the post-expression translocation of the protein to the membrane of the cell. Therefore, 
we deemed it prudent to acquire a new plasmid of 5-HT2B without the HA-tag sequence. When 
using this new plasmid, videos of the cells fluorescing showed that the transfection was slightly 
better and the cells fluoresced with slightly more consistency than with using the plasmid 
containing the HA-tag. In hopes of achieving greater improvement in the signal being produced 



























by the cells and in the degree/consistency of transfection, I decided to use this new plasmid 
(without the HA-tag) to produce a stable cell line containing 5-HT2B receptors with the HEK-293 T 
cells used for experiment. 
 After successful production of the stable cell line, data acquired from these cells was 
greatly improved with regards to transfection and signal generation. A majority of the cells cultured 
in the 96-well plates appeared to be transfected (~90%), when viewed under the microscope with 
the selected wavelengths (340 and 380 nm) and the new fluorescent indicator used, Fura-2. Fura-
2 is a calcium indicator which emits light at 510 nm when subjected to light with wavelengths of 
around 340 nm and 380 nm. A ratio of the fluorescence signal measured at both wavelengths is 
taken to generate a more accurate reading of Ca2+ release. Amongst the transfected cells ~80-
90% of cells appeared to produce consistent signals (i.e. produced approximately equal levels of 
fluorescence) when tested with 1 μM 5-HT. A concentration-response curve representing 5-HT 
activity is displayed in Figure 31. The pEC50 value from this curve (pEC50 = 8.8) is much closer to 
the literature value (pEC50 = 8.68)121 and variability in the concentration-response curve is much 



















Figure 31. Normalized (to 1 μM 5-HT) concentration-response curve of 5-HT at 5-HT2B receptors 
using the fluorescent microscope with stably transfected HEK293 cells. pEC50 = 8.8 ± 0.14 (EC50 
= 1.4 nM). 
  
Having finally developed a method by which to record accurate functional data for 
compounds at 5-HT2B receptors, the compounds mentioned above were tested. To address the 
first question of this aim (Is the binding of nFen at 5-HT2B receptors dependent on the electronic 
or lipophilic character of its 3-CF3 substituent?) concentration-response curves were acquired for 
nFen (20), 65, and 68 and are displayed below in Figure 32. The 3-CH3 analogue 65 is over five-
fold less potent (EC50 = 331 nM) than racemic nFen (EC50 = 65 nM), supporting the importance 
of the electronic character of the 3-CF3 substituent of nFen. However, activity of nFen was not 
completely abolished by replacement of 3-CF3 with 3-CH3 and this change still results in a 
compound with nanomolar potency (i.e., 65). Considering this small difference in potency, one 
possibility is that the 3-position substituent contributes little to nothing to the potency of the 3-
unsubstituted compound (i.e., amphetamine, 42). Hence, racemic amphetamine was evaluated 
for functional activity and was found to be inactive when examined at 10 μM concentration. From 



























this, it is evident that the 3-position substituents of 20 and 65 play an important role in agonist 
potency/action. There might be two possibilities: either the 3-CF3 substituent of nFen participates 
in both electronic and lipophilic interactions with binding site residues, or only participates in 
electronic interactions although lipophilic interactions with residues in a similar binding site region 
also elicit activity at 5-HT2B receptors (i.e. nFen and 65 participate in unique interactions via their 
3-position substituents e.g., rotameric binding). Translocation of the 3-CH3 substituent of 65 to 
the 4-position as in 68 resulted in similar potency (EC50 = 246 nM) as did 65. This supports the 
possibility of activating 5-HT2B receptors via lipophilic interactions with the phenyl substituents of 
these amphetamine analogues. Due to the similarity of the potencies of 65 and 68, it was 
predicted that the methyl substituents of both compounds participate in similar interactions with 
common residues in the binding site. The preliminary computational model with nFen and DOB 
supports this prediction: just as the phenyl rings of nFen and DOB were shifted in the binding 
pocket to accommodate similar interactions, so too might 65 and 68 be shifted relative to one 




























Figure 32. Normalized (to 1 μM 5-HT) concentration-response curves for functional activity of 
nFen (20), 65, and 68 at 5-HT2B receptors. pEC50 for nFen = 7.2 ± 0.20 (EC50 = 65 nM); pEC50 for 
65 = 6.5 ± 0.11 (EC50 = 331 nM); pEC50 for 68 = 6.6 ± 0.12 (EC50 = 246 nM). 
 
Computational docking and HINT analysis using the crystal structure of the 5-HT2B 
receptor (PDB ID: 6DRY) were conducted on 65 and 68 to determine their possible binding 
modes. Protein-ligand complexes were chosen based on those with the highest overall HINT 
score. Docked poses (Figure 33) revealed that both compounds bind very similarly to nFen and 
all three structures are nearly superimposed in the binding pocket. As expected, all three 
compounds participate in hydrogen bonding with Asp1353.32 via their amine nitrogen atoms. Just 













































































as predicted above, 68 assumed a shifted orientation with regard to its phenyl ring and the phenyl 
rings of nFen and 65, presumably to orient its phenyl substituent to be in the proper location in 
space for optimal interactions. Unlike in the case of norfenfluramine, HINT analysis did not reveal 
any hydrogen bonding between the phenyl substituents of 65 and 68 and binding site residues – 
which is expected as methyl groups are unable to form hydrogen bonds. Instead HINT analysis 
revealed several hydrophobic interactions with these substituents. For example, the 3-CH3 
substituent of 65 forms hydrophobic interactions with Val1363.33, Leu209EL2, and Phe2175.38, 
according to HINT. Similarly 4-methyl substituent of 68 interacts with Val1363.33 and Phe2175.38; 
additionally, HINT revealed hydrophobic interactions between the 4-methyl substituent and 
Ile1864.56, the β-carbon atom of Ser2225.43, and Ala2255.46. The modeling results add credence to 
the hypothesis that although electronic interactions with the phenyl substituents of these 
amphetamine compounds can elicit high activity, hydrophobic interactions with these substituents 
can also elicit activity, albeit to a slightly lower degree. It should be noted that HINT analysis failed 
to reveal any hydrophobic interactions involving the fluoro atoms of nFen; although, due to the 
close proximity between the fluoro atoms and hydrophobic residues (e.g. the hydrophobic 
residues that interact with the 3-CH3 substituent of 65), hydrophobic interactions may still 























Figure 33. Docking results of 65 and 68 in the binding site of the 5-HT2B receptor (cartoon 
helices/capped sticks rendering; green carbon atoms). A) Compound 65 (capped sticks rendering; 
cyan carbon atoms); B) Compound 68 (capped sticks rendering; orange carbon atoms); C) 
Overlay of 65, 68, and nFen (capped sticks rendering; magenta carbon atoms). Hydrogen bonds 





To address the second question of this aim (Is the 2-OCH3 substituent of DOB required 
for binding at 5-HT2B receptors?), DOB (22) and its des-2-methoxy analogue 71 were examined 
for their functional activity at 5-HT2B receptors. Concentration-response curves for both 
compounds are shown below in Figure 34. Removal of the 2-OCH3 substituent of DOB (EC50 = 
8.7 nM) as in 71 (EC50 = 67 nM) resulted in an almost eight-fold reduction in potency. This 
supports the necessity of the 2-OCH3 substituent of DOB for activity at 5-HT2B receptors. 
However, because 71 still retains nanomolar potency, it was concluded that although the 2-OCH3 
substituent might contribute to the greater potency of DOB through its electronic interactions with 
the oxygen atom or lipophilic interactions with the methyl group, it is not absolutely required for 
activity. These data are in accordance with very recent literature data166 indicating an 









Figure 34. Normalized (to 1 μM 5-HT) concentration-response curves for functional activity of 
DOB (22) and 71 at 5-HT2B receptors. pEC50 for DOB = 8.1 ± 0.20 (EC50 = 8.7 nM); pEC50 for 71 
= 7.2 ± 0.08 (EC50 = 67 nM). 
 
Computational docking and HINT analysis using the crystal structure of the 5-HT2B 
receptor (PDB ID: 6DRY) was re-conducted on 71; the selected protein-ligand complex produced 






















































the highest overall total interaction HINT score (2317) and is displayed in Figure 35 (Panel A). As 
expected, 71 participated in hydrogen bonding with Asp1353.32 via its amine nitrogen atom. 
Instead of forming a hydrogen bond with Asn3446.55 as observed in the docked model of DOB, 
the 4-Br substituent of 71 formed a weaker acid/base interaction. The docked poses of 71 and 
DOB were oriented similarly in the binding site but were slightly shifted relative to their phenyl 
rings. Furthermore, the phenyl rings are flipped relative to one another so the 3-OCH3 substituent 
of 71 and the 2-OCH3 substituent of DOB are facing the same direction. As a result, the methyl 
groups of both substituents participate in hydrophobic interactions with exactly the same residues, 
according to HINT analysis. They both form hydrophobic interactions with Val1363.33, the β-carbon 
of Ser1393.36, the -carbon of Thr1403.37, Ile1433.40, Ala2255.46, and Phe3416.52. However, unlike 
DOB which failed to possess any hydrogen bonding involving the 2-OCH3 oxygen atom, HINT 
analysis revealed a hydrogen bond interaction between the side-chain oxygen atom of Thr1403.37 
and the 3-OCH3 atom of 71. This is presumably made possible by the lower positioning of the 3-
OCH3 substituent of 71 compared to the 2-OCH3 substituent of DOB, thus being in a closer 
proximity for hydrogen bonding with Thr1403.37. Such a hydrogen bond might help salvage the 
activity of 71 and keep its activity in the nanomolar range, despite not producing any hydrogen 
bonding with Asn3446.55 as seen with DOB.  
Alternatively, docking results also produced a binding pose which most closely resembles 
the binding mode of DOB, with the 3-OCH3 substituent of 71 positioned in the same location as 
the 5-OCH3 substituent of DOB (Figure 35; Panel C); however, this solution had a slightly lower 
total interaction score (2240) than the solution in Panel A of Figure 35, described above.  As a 
result, the 4-Br substituent and the oxygen atom of the 3-OCH3 substituent formed hydrogen 
bonds with Asn3446.55 and the 4-Br substituent formed an additional hydrogen bond with 
Ser2225.43 – similar to the interactions involving DOB displayed in Figure 26. Furthermore, the 
methyl group of the 3-OCH3 substituent of 71 forms the same hydrophobic interactions as the 
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methyl group of the 5-OCH3 substituent of DOB: with Leu209EL2, Met2185.40, Phe3406.51, and 
Leu3627.35. Using this model, the reduced activity of 71 as compared with DOB can be supported 
by its lack of hydrophobic interactions: according to HINT analysis, DOB displays numerous 
hydrophobic interactions involving the methyl group of the 2-OCH3 substituent. Because 71 lacks 
the 2-position substituent, it is unable to form these hydrophobic interactions and this might result 
in its lower activity. The total energy for each suggested protein-ligand complex (shown in Figure 
35, panel A and C) was calculated using SYBYL. The energy for 71’s binding pose displayed in 
Panel A (-888 kcal/mol) is very similar to the energy for its binding pose displayed in Panel C (-






























Figure 35. Docking results of 71 in the binding site of the 5-HT2B receptor (cartoon helices/capped 
sticks rendering; green carbon atoms). A) Compound 71 (capped sticks rendering; yellow carbon 
atoms); B) Overlay of top total HINT interaction scoring 71 and DOB (capped sticks rendering; 
cyan carbon atoms); C) Overlay of top total HINT interaction scoring 71 (capped sticks rendering; 
peach carbon atoms) which most closely resembles the binding of DOB (capped sticks rendering; 





A series of other DOX phenylisopropylamine compounds was tested in 5-HT2B cells with 
the intent of elaborating their SAR for functional activity at 5-HT2B receptors. A total of nine 
phenylisopropylamine compounds with variable substituents at their 4-positions, DOB, DOI, DOF, 
DON, DOPR, DOTB, and MEM, were examined and concentration-response curves for six are 
displayed in Figure 36; data for DOB was shown in Figure 34. DOHx (33) and DOBz (35) failed 

















































Figure 36. Normalized (to 1 μM 5-HT) concentration-response curves for DOI (23), DOF (21), 
DON (30), DOPR (32), DOTB (34), and MEM (28). pEC50 for DOI = 7.4 ± 0.17 (EC50 = 39 nM); 
pEC50 for DOF = 6.4 ± 0.12 (EC50 = 439 nM); pEC50 for DON = 7.1 ± 0.12 (EC50 = 86 nM); pEC50 
for DOPR = 7.5 ± 0.17 (EC50 = 29 nM); pEC50 for DOTB = 7.4 ± 0.15 (EC50 = 37 nM); pEC50 for 
MEM = 6.3 ± 0.23 (EC50 = 557 nM). 
























































































































































Table 10. 5-HT2B potency, intrinsic efficacy, and affinity values of a series of DOX compounds: 









5-HT2B Ki (nM)111 
DOB (22) Br 8.7 ± 5.5 0.70 26.9 
DOI (23) I  39 ± 15 0.71 20.0 
DOF (21) F 439 ± 120 0.82 227 
DON (30) NO2  86 ± 24 0.77 166 
DOPR (32) n-Pr  29 ± 11 0.75 54.4 
DOTB (34) t-Bu 37 ± 13 0.69 24.6 
MEM (28) OC2H5 557 ± 296 0.70 763 
 
Note: 5-HT potency and efficacy at 5-HT2B receptors: 1.7 nM ± 0.59 and 0.92, respectively 
*Potency and intrinsic efficacy values normalized to 1 μM 5-HT 
  
When considering the effect of halogens occupying the 4-position of 
phenylisopropylamine compounds, it is evident that more lipophilic halogens with larger atomic 
radii are well tolerated. Compared to DOB (EC50 = 8.7 nM) and DOI (EC50 = 39 nM) which share 
similar functional activity, the activity of DOF is far lower (EC50 = 439 nM). This suggests that a 
strong lipophilic interaction between the 4-position substituent and lipophilic amino acids in the 
binding site might be beneficial for increasing activity at 5-HT2B receptors. Another possibility is 
that the halogen atoms are interacting with polar amino acids via halogen bonding through their 
positively charged σ-holes.  This can be resolved by considering the activity of DOPR (EC50 = 29 
nM) and DOTB (EC50 = 37 nM) which both contain 4-position alkyl chains capable of forming 
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significant hydrophobic interactions and have similar activity as DOB and DOI. This suggests that 
lipophilic interactions with the 4-position substituent can increase activity; however, polar 
interactions may still play a part. To test the importance of polar interactions with the 4-position 
substituent, DON and MEM were examined that contain 4-NO2 and 4-OCH2CH3 substituents, 
respectively. The activity of DON (EC50 = 86 nM) is almost 10-fold lower than its 4-bromo 
counterpart DOB, suggesting that charged substituents at the 4-position are tolerated but not 
optimal for activity. This might be due to a lack of polar amino acids capable of forming 
electrostatic interactions with the nitro substituent of DON such as arginine, lysine, aspartic acid, 
or glutamic acid in that region of the binding site. Furthermore, the activity of MEM, containing a 
hydrogen bond accepting oxygen atom, is far lower (EC50 = 557 nM) suggesting that there is even 
a lack of polar amino acids capable of forming hydrogen bonding interactions with the 4-position 
substituent. 
Because 5-HT2B receptor affinity data have been previously published by our group, it was 
of interest to correlate 5-HT2B functional activity to 5-HT2B affinity for the phenylisopropylamines 
examined above (Figure 37). These data would allow the determination of the predictive capability 
of affinity data to predict functional data (or vice versa) for these compounds. The correlation 
coefficient (r) for this plot is substantial (0.879), indicating that affinity and agonist potency are 
correlated to one another and thus Ki is a decent indicator of EC50. Nevertheless, 5-HT2B receptor 
affinity is not a valid predictor of functional activity because DOHx (33) and DOBz (35), although 
displaying high affinity (Table 3) were without agonist action at concentrations of up to 10,000 nM. 




















Figure 37. Relationship between 5-HT2B receptor affinity (pKi) and 5-HT2B receptor potency 
(pEC50) for seven DOX phenylisopropylamine compounds (slope = 0.962, r = 0.879). 
 
To examine the role of a 4-position substituent for binding affinity at 5-HT2B receptors, 
correlations were sought between 4-position substituent -values of phenylisopropylamine 
agonists and their affinity at 5-HT2B receptors as well as between 4-position substituent σp-values 
and affinity (Figure 38). There is a much stronger correlation between -values and affinity (r = 
0.787) than between σp-values and affinity (r = 0.064), suggesting that hydrophobic interactions 
with the 4-position substituent might be the primary driving force for the binding of these 





















Figure 38. A) Relationship between 4-position substituent -values of phenylisopropylamine 
agonists and their 5-HT2B receptor affinity (pKi) (slope = 0.554, r = 0.787). B) Relationship between 
4-position substituent σp-values of 4-position substituents of phenylisopropylamines and their 5-





 To determine if the potency values of these compounds follow the same trend as their 
affinity values, their EC50 values, acquired in the present study, were analyzed and compared with 
both the 4-position substituent -values of phenylisopropylamine agonists as well as with their 4-
position substituent σp-values (Figure 39). The correlation between pEC50 values and  values 
was greater (r = 0.634) than the correlation between pEC50 values and σp-values (r = 0.193). 
Thus, similarly to the case of affinity, potency also might be driven by the lipophilicity of the 4-
position substituent of phenylisopropylamines and the resulting hydrophobic interactions it 
participates in. It is entirely possible that both the lipophilic and electronic character of DOX 4-
position substituents contribute to activity. Thus, a relating equation involving both  and σ might 
be developed. Indeed, a preliminary study was conducted employing both variables and resulted 
in a relating equation where r > 0.8. However, given that data on only seven compounds were 
available, the equation was not statistically valid. Additional agonists will need to be examined in 




























Figure 39. A) Relationship between 4-position substituent -values of phenylisopropylamine 
agonists and their 5-HT2B receptor potency (pEC50) (slope = 0.489, r = 0.634). B) Relationship 
between 4-position substituent σp-values of 4-position substituents of phenylisopropylamines and 




The overall goal of this project was to elaborate on the pharmacophoric requirements of 
5-HT2A and 5-HT2B receptors. In Aim 1, the pharmacophoric requirements of 5-HT2A receptor 
antagonism was investigated – based on the structure of risperidone and with the specific 
intention of “elaborating” (using the DRE approach) the fluorinated pharmacophore 14 to 
determine the effects of adding N-substituents on 5-HT2A affinity. Previous studies revealed that 
the entire structure of risperidone is not required for activity and only the right half portion as in 14 
is necessary for activity. A 5-HT2A receptor affinity screen conducted on 14, its N-methylated 
analogue 15, and other analogues containing substituents on the piperidinyl nitrogen atom of 
varying length and sizes (10, 16-18, and 51) revealed that although increasing the length and bulk 
of the piperidinyl substituent is correlated with greater 5-HT2A receptor affinity and selectivity, it is 
also correlated with increased D2 receptor affinity. One potential application of this project was to 
develop a safer antipsychotic drug by increasing the 5-HT2A receptor antagonism and selectivity 
of atypical antipsychotic drugs and concurrently decreasing their D2 receptor antagonism (and 
thus increasing the safety of these drugs by reducing their incidence of EPS symptoms). In this 
scope, the results of the affinity screen conducted and the resulting trends surmised from the data 
indicate that extension of the piperidinyl substituent of 14 might not result in a compound that 
would make a better antipsychotic drug due to the associated trend in greater D2 receptor affinity. 
In addition, affinity data of the synthesized compound 53, containing a propyl substituent on the 
piperidinyl nitrogen atom, revealed that although a methyl substituent is well tolerated as in 15 
and results in greater affinity (Ki = 12.3 nM) relative to 14 (Ki = 71.4 nM), increasing the length to 
a propyl chain results in a reduction of affinity (Ki = 107 nM). This indicates that longer alkyl chains 
than methyl are less tolerated at 5-HT2A receptors, further supporting the indication that extension 
of the piperidinyl nitrogen atom substituent might not result in a good antipsychotic drug. However, 
putting the intention of developing safer antipsychotic drugs aside, further SAR evaluation based 
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on the structure of 14 is still essential for having a more comprehensive understanding of the 
structural requirements for 5-HT2A affinity and selectivity. To accomplish this, future affinity 
screens of the compounds designed in this aim (52, 54, and 55) can be conducted. These data 
would refine the trend in SAR of simple alkyl chain substituents on the piperidinyl nitrogen atom 
on 5-HT2A affinity and selectivity. Possibly, the reason why the affinity of 53 decreases relative to 
15 is that longer substituents than a methyl group require an aromatic and/or a heteroatom-
containing moiety. If there exists an aromatic requirement, 55 should result in greater affinity than 
53 and 54. Other longer alkyl chains (containing four carbon atoms or more) containing amine or 
hydroxy moieties should also be examined to determine if electrostatic interactions are crucial to 
5-HT2A affinity. 
 To further refine the SAR for 5-HT2A receptor activity, quipazine (45), isoquipazine (46), 2-
NP (47), and 1-NP (48) were examined in Aim 2 in a computational modeling study using crystal 
structures of the 5-HT2A receptor. Specifically, the intention was to determine probable binding 
modes of these compounds to suggest reasons for their peculiar activities. HINT analysis results 
of the chosen binding poses are in accordance with the binding activities of these compounds. 
For example, the higher affinity compounds 2-NP and 1-NP display greater total interaction scores 
(1496 and 1454, respectively) than their structural counterparts and lower affinity compounds 
quipazine (899) and isoquipazine (1121), respectively. It is predicted that hydrophobic interactions 
might be paramount for the high affinity of this class of compounds as both 2-NP and 1-NP occupy 
a distinct binding pocket that contains more hydrophobic residues as compared to the binding 
pocket occupied by quipazine and isoquipazine. This is supported by the higher total hydrophobic 
scores of 2-NP (501) and 1-NP (649) compared with quipazine (239) and isoquipazine (479). One 
important question of this aim was: why does the addition of a nitrogen atom in the aromatic rings 
of 2-NP and 1-NP (as with quipazine and isoquipazine) result in such a reduction of affinity? The 
identified binding poses for these compounds addresses this question. Both quipazine and 
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isoquipazine formed electrostatic interactions with Ser1593.36 and Asn3436.55, respectively. It is 
predicted that because they participate in these interactions, quipazine and isoquipazine are 
“forced” to occupy a distinct pocket as compared to 2-NP and 1-NP, thus rendering them unable 
to participate in hydrophobic interactions that would otherwise confer higher affinity. 
 It should be noted that isoquipazine and 1-NP, the antagonists in this study, are 
structurally simple compounds and represent another pharmacophore for 5-HT2A receptor 
antagonism. It could be argued that 1-NP represents a truer antagonist pharmacophore as 
compared to that derived in Aim 1 (des-fluoro analogue of 14) due to its simpler structure: while 
both structures contain biaryl ring moieties bonded to unconjugated six-membered nitrogen atom-
containing rings, 1-NP contains one fewer heteroatom in its structure. Based on the structure of 
1-NP, simple deconstruction analyses can be conducted, particularly one that determines the 
necessity of the tertiary nitrogen atom. The piperazine ring can also be broken open, resulting in 
a long chain, to determine the importance of the ring for activity. If the piperazine ring is important 
for activity, the ring nitrogen atoms can be translocated through the ring to determine their optimal 
location. 
 The premise for the third aim was contrived from preliminary modeling studies utilizing 
docked structures DOB and nFen in the binding site of the 5-HT2B receptor. These modeling 
studies drew attention to potential electrostatic interactions employed by both molecules to bind 
with residues. Specifically, HINT analysis revealed hydrogen bonds/acid base interactions 
involving the 5-OCH3 and 4-Br substituents of DOB and the 3-CF3 substituent of nFen. These 
results thus called into question the necessity of the 2-OCH3 substituent of DOB and the 
electrastic/hydrophobic participation of the 3-CF3 substituent of nFen (because fluoro atoms are 
capable of forming both hydrogen bonds and hydrophobic interactions with residues). To 
determine the involvement of these substituents, 65, 68, and 71 were synthesized and examined 
in a Ca2+-release assay utilizing HEK-293T cells stably transfected with the 5-HT2B receptor 
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plasmid, along with nFen and DOB as standards. To confirm that nFen’s agonist activity at 5-HT2B 
receptors is dependent on the 3-CF3 substituent, amphetamine was also examined. Results 
indicated amphetamine is inactive as an agonist (at 10 μM) at 5-HT2B receptors, confirming the 
essential nature of the 3-CF3 substituent. Furthermore, this substituent most likely interacts with 
the binding site in a hydrophobic or both a hydrophobic and an electrostatic manner with the 
binding site, supported by functional activity results: although 65 (EC50 = 331 nM) resulted in over 
five-fold lower potency as compared with nFen (EC50 = 65 nM); both 65 and its positional isomer 
68 (EC50 = 246 nM) resulted in low-nanomolar potency suggesting that hydrophobic interactions 
are very favorable for 5-HT2B agonist activity. If electrostatic interactions were paramount for 
agonist activity, it is unlikely to observe such a large increase in agonist activity when comparing 
amphetamine to 65. Not only did we observe high potency for the 3-CH3 analogue 65, we also 
observed similarly high potency for the 4-CH3 analogue 66, suggesting hydrophobic interactions 
might be so crucial, interaction can occur with both the 3- and 4-position substituents without 
much difference in potency.   
Computational docking studies of nFen, 65, and 68 revealed a similar positioning of their 
phenyl substituents in the binding site of the 5-HT2B receptor as well as numerous hydrophobic 
residues near this region capable of interacting with 3- and 4-position substituents of these 
amphetamine analogues, supporting the hypothesis that hydrophobic interactions are paramount 
for the activity of nFen.  
 Functional activity analysis of 71 revealed that although the 2-OCH3 substituent of DOB is 
not absolutely essential for functional activity, it does contribute: compound 71 (EC50 = 67 nM) 
resulted in an almost eight-fold reduction in potency as compared to DOB (EC50 = 8.7 nM). 
Computational docking results produced a potential binding pose for 71 based on the highest total 
interaction score from HINT analysis. This binding pose does not have its 3-OCH3 substituent 
superimposed with the 5-OCH3 substituent of DOB. Instead, 71’s 3-OCH3 substituent faces the 
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same direction as the 2-OCH3 substituent of DOB, enabling methyl groups from both substituents 
to participate in identical hydrophobic interactions with the same binding site residues, supported 
by HINT. The 3-OCH3 oxygen atom also forms a hydrogen bond with Thr1403.37, which might 
contribute to 71’s retention of nanomolar potency; 71 lacks the hydrogen bonds with Ser2225.43 
and Asn3446.55 as observed in the model of DOB, therefore the hydrogen bonding with Thr1403.37 
might make up for this deficit of interaction. 
 A more logical representation of the binding of 71 at 5-HT2B receptors is depicted in Panel 
C of Figure 35 which displays 71 essentially superimposed with DOB in the binding site. Due to 
the structural similarity between 71 and DOB, logic would suggest that both compounds would 
bind similarly. Although this binding pose did not produce the highest total interaction HINT score, 
it was still amongst the top 20 highest scoring solutions out of the 100 solutions generated and 
examined. Thus, this model is still a very viable candidate for the accurate representation of 71’s 
binding. HINT analysis revealed that 71 participates in identical hydrogen bond interactions with 
Ser2225.43 and Asn3446.55 via its 4-Br and 3-OCH3 substituents, as compared with DOB. The 
almost eight-fold lower potency of 71 compared with DOB can be explained by its lack of a 2-
OCH3 substituent, thus rendering it unable to participate in hydrophobic interactions via the methyl 
group (as observed with DOB). This model is a better representation of this difference in activity 
than the model discussed previously. In the previous model, 71 did not display any hydrogen 
bonding with Ser2225.43 nor with Asn3446.55 via its 4-Br substituent. Such a loss of hydrogen bond 
interaction is likely to result in a much more drastic reduction in potency, due to the high energy 
of these bonds. Instead, the slightly lower potency of 71 compared with DOB is much better 
explained by the lower hydrophobic interactions (a weaker type of bond) experienced by 71.  
Another explanation is that the majority of DOB’s agonist effect is elicited by hydrophobic 
interactions via its 4-Br substituent, which would be more congruent with the hypothesis stated 
above (hydrophobic interactions are paramount for the 5-HT2B activity of these analogues). 
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Continuing with the same reasoning, the methoxy substituents of DOB may contribute very little 
to its potency. It was determined in this study that the 2-OCH3 substituent is not essential for 
activity, however there is also evidence that the 5-OCH3 might not be necessary as supported by 
the high potency of 65 that contains no substituents capable of forming electrostatic interactions 
such as a methoxy substituent. Because of the similar lipophilicity of bromo ( = 0.86)164 and 
methyl ( = 0.56)164 substituents, simply a 4-Br substituent with no other phenyl substituents might 
be enough to elicit high potency. However, the bromo and methyl substituents contain opposite 
electronic character (σp = 0.23 and -0.17, respectively), thus there is still a possibility for electronic 
contribution of the 4-Br substituent of DOB. To conclude, the 2-OCH3 substituent of DOB is not 
required for its agonist activity at 5-HT2B receptors, unlike in the case of 5-HT2A receptors where 
removal of the 2-OCH3 substituent results in abolishment of affinity. With this simple revelation, 
we can already begin to separate the activity of compounds at 5-HT2A and 5-HT2B receptors. 
Furthermore, removal of the 5-OCH3 substituent results in a drastic reduction of affinity for 5-HT2A 
receptors. Future studies examining other amphetamine analogues such as 4-
bromoamphetamine should be conducted to definitively test for the necessity of the 3-OCH3 
substituent of 71. 
 Another goal of this aim was to gain understanding with regards to the SAR of 
phenylisopropylamines at 5-HT2B receptors. To accomplish this, a series of 
phenylisopropylamines (DOB, DOI, DOF, DON, DOPR, DOTB, and MEM) were examined for 
their functional activity at 5-HT2B receptors. It was discovered that larger, more lipophilic halogen 
substituents are best tolerated, as supported by the vast difference in activity of DOF (EC50 = 439 
nM) which contains a smaller, less lipophilic 4-F substituent, compared to the activity of DOB 
(EC50 = 8.7 nM) and DOI (EC50 = 39 nM) which contain larger and much more lipophilic 4-position 
substituents. The importance of the lipophilic nature of the 4-position substituent is substantiated 
by the data obtained from DOPR and DOTB. Both compounds produced approximately equal 
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potency, similar to that produced by DOI. Assuming that these phenylisopropylamines bind 
similarly to the proposed binding mode of the amphetamine analogues examined above (65 and 
68, Figure 33), and 71 and DOB (Figure 35), numerous hydrophobic residues (Val1363.33, 
Leu209EL2, Phe2175.38, Ile1864.56, and Ala2255.46) are available within interacting distance of the 
4-position substituent, thus explaining the high activities of DOPR (EC50 = 29 nM) and DOTB 
(EC50 = 37 nM) which both contain lipophilic 4-position alkyl chain substituents capable of forming 
hydrophobic interactions. DOB and DOI might additionally participate in hydrogen bonding 
interactions with residues such as Ser2225.43 and Asn3446.55 as depicted in the docked model of 
DOB (Figure 35), contributing to their high activities. The lower activity of MEM might suggest that 
electron withdrawing substituents are not very well tolerated at the 4-position.  
Given the combined results from Aim 3, the pharmacophore model in Figure 27 can be 
refined. It was proposed that the phenyl substituents of the pharmacophore can contain 
substituents either in the 3- or 4-positions capable of forming electrostatic or hydrophobic 
interactions with the binding site. Our functional assay data for 65 and 68 revealed that methyl 
substituents are well tolerated at both the 3- and 4-positions of the phenyl rings. Thus our model 
can be refined to specify that both hydrophobic interactions with 3- and 4-position phenyl 
substituents of amphetamine-like compounds elicit activity at 5-HT2B receptors (Figure 40); 
however, electrostatic interactions might still contribute to greater activity as portrayed by the 















Figure 40. Revised pharmacophore for 5-HT2B receptor agonist action. 
This revised model also accounts for the agonist actions of the DOX analogues. Although 
a role for possible electrostatic interactions cannot be eliminated, it would appear that hydrophobic 
interactions play a dominant role, but that the site these substituents interact with is of limited size. 
Compounds with large lipophilic substituents bind (e.g., DOHx, DOBz) with affinities nearly 





























Compounds were characterized using mass spectrometry (MS), proton nuclear magnetic 
resonance (1H NMR), and melting point analysis using the Thomas Hoover melting point 
apparatus. The 1H NMR used was a Bruker AXR 400 MHz spectrometer using tetramethylsilane 
(TMS) as an internal standard. The positions of the peaks in the 1H NMR spectra were reported 
as parts per million (δ). The coupling constants (J, Hz) and integration values were reported for 
all compounds. The splitting pattern of the peaks were also reported as containing either singlets 
(s), doublets (d), triplets (t), quartets (dd) doublet of doublets (td), triplet of doublets, (td), or 
multiplets (m). Reactions were monitored using thin layer chromatography (TLC) using silica gel 
GHLF plates. Purification of compounds was done using flash chromatography (ComiFlash 
Companion/TS) and recrystallization methods. All compounds were prepared as hydrochloride 
salts. 
 
6-Fluoro-3-(piperidin-4-yl)benz[d]isoxazole Hydrochloride (14) 
Crude compound 61 (1.0 g, 4.03 mmol) was dissolved in anhydrous EtOH (25 mL) and was added 
to a stirred mixture of HCl (1.4 mL) in anhydrous EtOH (10 mL) under an N2 atmosphere.  The 
resulting mixture was heated at reflux for 3 h and was allowed to stand at room temperature for 
five days.  The resulting precipitate was collected by filtration and was recrystallized from 
MeOH/Et2O to yield 0.07 g of 14 (8%) as a buff colored solid: mp 298-302 °C (lit.159 293-295 °C). 
No further characterization of the compound was conducted. 
 
6-Fluoro-3-(1-propyl-4-piperidyl)-1,2-benzoxazole Hydrochloride (53) 
Compound 14 (1.0 g, 4.5 mmol) was dissolved in acetonitrile and 1-iodopropane (0.53 mL, 5.45 
mmol) and K2CO3 (1.9 g, 13.6 mmol) were added. The mixture was heated at reflux for 15 h, 
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cooled to rt and K2CO3 was filtered and washed with acetonitrile. The filtrate was concentrated to 
an oil and the oil was purified using column chromatography (EtOAc/MeOH). Ethereal HCl was 
added in a dropwise manner to the freebase dissolved in Et2O forming the final compound 53 as 
an HCl salt which was purified by recrystallization using MeOH/Et2O yielding 0.07 g of 53: mp 
200-204 °C (lit.160 mp 208-210 °C); 1H NMR (DMSO-d6) δ 0.88-1.04 (m, 3H, CH3), 1.62 (s, 1H, 
CH), 1.80-2.23 (m, 4H, CH2, CH2), 2.70-3.01 (m, 4H, CH2, CH2), 3.01-3.26 (m, 2H, CH2), 3.27-
3.50 (m, 1H, CH), 3.60-3.75 (m, 2H, CH2), 7.01-7.27 (m, 1H, CH), 7.54 (dd, J = 4.99, 3.77 Hz, 1H, 
CH), 8.32 (dd, J = 5.11, 3.78 Hz, 1H, NH+); HRMS (ESI-TOF) m/z [M + H]+ calcd for C15H20FN2O, 
236.1556; found, 236.1550. 
 
N-Formylpiperidine-4-carboxylic acid (57) 
AC2O (28.5 mL) and HCOOH (11.4 mL) were stirred for 1 h at 60 °C under an N2 atmosphere and 
gradually cooled to 0 °C using an ice-bath.  Isonipecotic acid (6.5 g, 50.3 mmol) was added 
portionwise and the reaction mixture was stirred for 16 h at room temperature.  The solvent was 
evaporated under reduced pressure and the resulting pale white solid was recrystallized from i-
PrOH to yield 5.3 g (68%) of 57 as a white solid: mp 134-137 °C (lit.167 136-138 °C). 
 
N-Formylpiperidine-4-carboxylic acid chloride (58) 
Compound 57 (5.3 g, 34.0 mmol) was added portionwise to SOCl2 (5.1 mL) which had been stirred 
and cooled to 0 °C.  DMF was added and the reaction mixture was allowed to stir at room 
temperature overnight under an N2 atmosphere.  SOCl2 was evaporated under reduced pressure 
to yield 9.0 g of an orange oil.  The crude oil was used without further characterization for the 







AlCl3 (11.7 g, 87.7 mmol) was added portionwise to a stirred mixture of 58 (9.0 g, 51.3 mmol) in 
1,3-difluorobenzene (36.2 mL), under an N2 atmosphere.  The reaction mixture was heated at 
reflux for 3 h and was quenched by pouring the reaction mixture into ice-H2O.  The aqueous 
mixture was extracted with CHCl3 (3 x 50 mL) and the combined organic portion was washed with 
H2O (1 x 50 mL), dried (MgSO4) and evaporated under reduced pressure to yield 11.9 g of a dark 




Compound 59 (3.0 g, 12 mmol) was dissolved in anhydrous EtOH (45 mL) and the resulting 
solution was added dropwise to a stirred solution of hydroxylamine hydrochloride (2.5 g, 36 mmol) 
in anhydrous EtOH (48 mL) under an N2 atmosphere.  A solution of NaOH (1.49 g, 37.2 mmol) in 
H2O (9.3 mL) was added to the reaction mixture.  The reaction mixture was heated at reflux 
overnight under an N2 atmosphere.  The resulting precipitate was removed by filtration and the 
filtrate was evaporated under reduced pressure, yielding a yellow solid which was recrystallized 
from H2O, yielding 1.2 g (36%) of 60 as a pale yellow solid: mp 182-186 °C (lit.159 182-184 °C). 
 
N-Formyl-4-(6-fluorobenz[d]isoxazol-3-yl)piperidine (61) 
Compound 60 (1.2 g, 4.4 mmol) was dissolved in anhydrous DMF (12 mL) and was stirred under 
an N2 atmosphere.  The solution was added dropwise to toluene-washed NaH (0.2 g, 8.7 mmol).  
The reaction mixture was heated at 75 °C for 4 h and was allowed to stir under an N2 atmosphere 
for 96 h.  The reaction mixture was quenched by pouring the mixture into H2O.  The aqueous 
mixture was extracted with EtOAc (3 x 30 mL) and the combined organic portion was washed with 
H2O (1 x 50 mL), dried (MgSO4) and concentrated under reduced pressure, yielding 1.0 g (93%) 





3-Methylbenzaldehyde (63, 2.0 g, 16.6 mmol) and NH4OAc (1.8 g, 22.7 mmol) were stirred and 
heated at reflux in nitroethane (33.3 mL for 48 h. The reaction mixture was poured into H2O (10 
mL). The mixture was extracted (3 x 30 mL) with EtOAc and the combined EtOAc fraction was 
washed with brine and dried (MgSO4). Evaporation of EtOAc under reduced pressure resulted in 
a crude oil which was purified using column chromatography resulting in 1.6 g (54%) of the pure 
oil 64 which was used in the preparation of 65. 
 
1-(3-Methylphenyl)propan-2-amine Hydrochloride (65) 
A suspension of LiAlH4 (2.4 g, 62.5 mmol) in THF (47 mL) was added using an addition funnel to 
64 (1.6 g, 8.9 mmol). The solution was heated under reflux for 2 h. Reaction mixture was 
quenched with H2O (2.4 mL), 15% NaOH aq. solution (2.4 mL), and H2O (7.1 mL), resulting in 
white crystals (Li and Al salts) which were filtered off and washed with Et2O. The filtrate was dried 
(MgSO4) and concentrated to an oil. The oil was purified using column chromatography (silica 
gel; CHCl3/MeOH). The oil was dissolved in Et2O and concentrated ethereal HCl was added in a 
dropwise manner until the solution turned acidic. 0.2 g (13%) of the solid 65 was collected by 
vacuum filtration: mp 134-135 °C (lit.168 mp 113-115 °C); 1.15 (d, J = 6.5 Hz, 3H, CH3), 2.35 (s, 
3H, CH3), 2.66 (dd, J = 9.4 Hz, 1H, CH2), 3.07 (dd, J = 4.9 Hz, 1H CH), 3.38-3.43 (m, 1H, CH), 
7.07-7.13 (m, 3H, CH), 7.27 (tr, J = 7.5 Hz, 1H, CH), 8.22 (s, 3H, NH3+). 
 
(E)-1-Methyl-4-(2-nitropropen-1-yl)benzene (67) 
4-Methylbenzaldehyde (66, 2.0 g, 16.6 mmol) and NH4OAc (1.8 g, 22.7 mmol) were stirred and 
heated at reflux in nitroethane (33.3 mL) overnight. The reaction mixture was poured into H2O (10 
mL). The mixture was extracted with EtOAc (3 x 30 mL) and the combined EtOAc fraction was 
washed with brine and dried (MgSO4). Evaporation of EtOAc under reduced pressure resulted in 
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a crude oil, which mostly solidified under vacuum. The solid was filtered and washed with cold 
EtOH. The solid was recrystallized from EtOH affording 1.52 g (52%) of 67 as a yellow colored 
solid. 67 was used in the preparation of 68. mp 55-56 °C (lit.169 mp 53-54 °C). 
 
1-(4-Methylphenyl)propan-2-amine Hydrochloride (68) 
A suspension of LiAlH4 (1.5 g, 39.5 mmol) in THF (30 mL) was added using an addition funnel to 
67 (1 g, 5.6 mmol). The solution was heated at reflux for 2 h. The reaction mixture was quenched 
with H2O (1.5 mL), 15% NaOH aq. solution (1.5 mL), and H2O (4.5 mL), resulting in white crystals 
(Li and Al salts) which were filtered off and washed with Et2O. The filtrate was dried (MgSO4) and 
concentrated to an oil. The oil was purified using column chromatography (silica gel; 
CHCl3/MeOH). The resulting oil was dissolved in Et2O and concentrated ethereal HCl was added 
in a dropwise manner until the solution turned acidic. The resulting solid was collected by vacuum 
filtration affording 0.04 g (13%) of the final compound 68 as a white solid. mp 155-156 °C (lit.168 
mp 148-150 °C); 1H NMR (DMSO-d6) δ 1.10 (d, J = 6.5 Hz, 3H, CH3), 2.29 (s, 3H, CH3), 2.62 (dd, 
J = 9.2 Hz, 1H, CH2), 2.99 (dd, J = 13.2 Hz, 1H, CH2), 3.34 (m, 1H, CH), 7.14 (dd, J = 8.2 Hz, 2H, 
CH), 8.09 (s, 3H, NH3+). 
 
(E)-1-Bromo-2-methoxy-4-(2-nitropropen-1-yl)benzene (70) 
3-Methoxy-4-bromobenzaldehyde (69, 0.3 g, 1.4 mmol) and NH4OAc (0.7 g, 9.1 mmol) were 
heated to reflux in nitroethane (10 mL) overnight. The reaction mixture was poured into H2O (10 
mL). The mixture was extracted with EtOAc (3 x 15 mL) and the EtOAc layer was washed with 
brine and dried over MgSO4. Evaporation of EtOAc under reduced pressure resulted in a crude 
oil, which was purified using column chromatography (silica gel; hexane/EtOAc) affording 0.2 g 





1-(4-Bromo-3-methoxyphenyl)propan-2-amine Hydrochloride (71) 
NaBH4/BF3 (0.97 g, 2.6 mmol) was added to a round bottom flask and cooled to 0 °C. THF (7 mL) 
was added, the ice bath was removed, and the contents were stirred for 15 min; 70 in THF (3 mL) 
was added and the reaction mixture was stirred at reflux for 5.5 h. The mixture was cooled to rt, 
quenched with H2O (6.8 mL), acidified (1 N HCl, 6.8 mL) and heated at 85 °C for 2 h. The mixture 
was cooled to rt and the acid layer was washed with Et2O (2 x 10 mL) and basified with 5 M 
NaOH. The solution was extracted with Et2O (3 x 15 mL). The organic layer was dried (MgSO4) 
and concentrated to an oil. The oil was dissolved in Et2O and ethereal HCl was added to form a 
solid. The solid was filtered and recrystallized with MeOH/Et2O affording 0.048 g (32%) of 71. mp 
= 145-150 °C (lit.166 mp = 151-152 °C); 1H NMR (DMSO-d6) δ (d, J = 1.15, 6.5 Hz, 3H, CH3), (dd, 
J = 2.72, 8.2 Hz 1H, CH), (dd, J = 2.97, 5.8 Hz 1H, CH), (s, J = 3.45, 1H CH), (s, J = 3.86, 3H, 
CH3), (d, J = 6.78, 8 Hz, 1H, CH), (s, J = 7.04, 8.2 Hz, 1H, CH), (d, J = 7.51, 8 Hz, 1H, CH), (s, J 
= 8.11, 3H, NH3+) 
 
B. Computational Docking 
All compounds were sketched using SYBYL-X 2.1.1 and were energy minimized utilizing 
the Tripos Force Field with Gasteiger-Hückel charges, a non-bonded interaction cutoff of 8 Å, 
dielectric constant (ε) of 4.00 D/Å, and a termination gradient of 0.05 kcal/(mol*Å). The structures 
were then docked at either the 5-HT2B receptor crystal structure (active, PDB: 6DRY) or 5-HT2A 
crystal structures [active (PDB: 6WHA) or inactive (PDB: 6A94)] using GOLD v5.6 which 
generated up to 100 protein-ligand complexes for each compound and GOLD scores, based on 
an in-program scoring system, for each complex. Complexes were then energy minimized using 
SYBYL-X 2.1.1 and evaluated by HINT score analysis within SYBYL 8.1. A built-in GOLD 
clustering program (using an RMSD cutoff of 0.75 Å) was used in conjunction with the docking of 
quipazine (45), isoquipazine (46), 2-NP (47), and 1-NP (48). The resulting clusters were analyzed 
according to which one contained the highest scoring GOLD solution [highest scoring cluster 
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(HSC)] and which one contained the most number of solutions [most populated cluster (MPC)]. 
The final binding poses for quipazine and isoquipazine were selected because they were the 
highest GOLD-scoring solutions. The binding poses for 2-NP and 1-NP were selected because 
they were the highest scoring solutions within the MPC. The binding mode of R(-)-DOB was 
selected because it produced the highest GOLD score. The binding mode of S(+)-nFen was 
selected because it produced the highest GOLD-scoring solution that most closely resembled the 
binding mode of R(-)-DOB. The binding modes for S-64, S-68, and R-71 were selected because 
they produced the highest overall HINT interaction scores. An additional binding mode for R-71 
was proposed because it was the highest HINT interaction-scoring pose which most closely 




C. Functional Activity Studies 
Functional activity studies of the compounds were conducted using a Ca2+ binding assay 
using the epifluorescent microscope (Olympus IX71). Cells used for experiments were cultured 
using Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS) and 
5% penicillin/streptomycin. The fluorescent indicator used during experiments was Fura 2-AM. 
Cells were analyzed using wavelengths of 340 nm and 380 nm, bandwidth of 12 nm, light intensity 
of 15%, and exposure of 70 ms. Three wells containing cells were analyzed for each concentration 
per experiment day. Two experiments were conducted for each drug. All data was processed 
used Fiji software by ImageJ2 which allowed manual selection of cells and measurement of 
fluorescence. Logarithmic concentration-response curves were generated using Graphpad Prism 
8. Curves were generated with a Hill slope of 1.0 to allow easier comparison of potencies of the 
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